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Alveolar macrophages are found in a truly unique microenvironment of the lung alveoli, where 
they are in close contact with the respiratory epithelium. This close contact with the epithelium 
is essential as it is how these highly inflammatory cells (cells that respond quickly to immune 
response as dysregulation of homeostasis exacerbates pathology) are regulated to prevent 
excessive inflammation, which otherwise would damage the lung, possibly leading to Asthma 
or COPD. Meaning that in the absence of pathology, the inflammatory response of alveolar 
macrophages are limited. Interaction with the lung occurs when macrophages bind to the 
epithelium through a specific receptor such as CD200R and possibly Siglec-F. Siglec-F is a 
lectin on the surface of macrophages that binds glycoconjugates containing sialic acid on the 
lung epithelium and on mucins, which is speculated to negatively regulate alveolar 
macrophages. Though the specific role of Siglec-F as a regulator of macrophage is not fully 
understood. 
The aim of this project is to explore changes in gene expression and functional outcomes of 
signalling through Siglec-F.  An exogenous system was used to stimulate this receptor using 
antibody crosslinking, which is then confirmed by analysing recruitment of SHP-1 in western 
blot. We also aim to measure differences in cytokine production using a multiplex kit which can 
simultaneously measure several different cytokines. Lastly, we aim to use RNA sequencing to 
analyse changes in gene expression. This data will then be used to propose functional outcomes 
of Siglec-F signalling; improving the understanding of the role of the receptor in negative 
regulation of alveolar macrophages. 
The western blot results showed successful recruitment of SHP-1 and thus successful targeting 
of Siglec-F. We also observed a reduction in proinflammatory cytokines TNF-α, IL-6, CXCL1 
and anti-inflammatory cytokine TGF-β1 when crosslinked with Siglec-F in the presence of a 
known strong stimulator of the innate immune response (LPS). This reduction of cytokines 
indicates a negative regulatory function of the Siglec-F receptor, though potential functional 
effector functions of Siglec-F is not understood. Looking at changes in expression we found 
interesting putative targets of the Siglec-F signalling pathway including immune related genes 
such as TREM2, Axl, and IL-6 as well as other genes associated with RNA synthesis and the 
control of protein translation. This study will provide information about the effector functions of 





Statement of Originality  
There is evidence to support the role of CD200R, TGF-β and IL-10 as regulators of 
homeostasis, however there is only partial evidence for Siglec-F. In order to gather more 
evidence for the role of Siglec-F as a macrophage regulator; the changes in whole genome 
expression in alveolar macrophages after stimulation with crosslinked Siglec-F will be explored. 
It is then possible to link changes in genome expression to effector functions. These effector 
functions could overlap with existing regulatory functions or could be new regulatory functions 
not currently associated with other regulators.  
This research aims to investigate the outcome of signalling through Siglec-F in mouse alveolar 
macrophage by whole genome expression using a highly specific antibody crosslinking system, 
with the possibility of creating new avenues for specialised treatment in diseases such as COPD 
and asthma.  
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1.1 An introduction into resident macrophages 
Tissue resident macrophage function is tailored to the tissue/organ they reside in; this allows 
macrophages to become specialised to the tasks required by the microenvironment. For 
example, Kupffer cells whose primary function is to remove protein complexes, small particles, 
dying red blood cells, and cell debris from portal blood flow (Kawada and Parola, 2015). 
Whereas osteoclasts have become so specialised that they are the only cell capable of bone 
degradation (Ross, 2011). Alveolar macrophages are another type of resident macrophages 
which are specialised to live outside the body in the lumen of the lung alveoli. These cells have 
also adapted to be highly inflammatory sentinels (Mathie et al., 2014) as well as efficient 
removers of dust particles, pathogens, pollutants and dead cells that could interfere with the 
diffusion of gases. The clearance and recycling of the cells being essential to the host survival 
(Mosser and Edwards, 2008). 
 
Macrophages are characterised by their diversity and plasticity, allowing macrophages in tissues 
to respond to different environmental triggers such as: microbes, dead or damaged cells, 
cytokines produced by activated leukocytes and epithelial cells with distinct functional 
phenotypes (Hussell and Bell, 2014). This ability to adapt and to carry out several different 
functions led to the now limited and broad classification of the two main types of polarised 
macrophages: the classically activated M1 macrophage and the alternatively activated M2 
macrophage. Exposure to pro-inflammatory molecules such as IFN-γ has a strong association 
with classically activated macrophage phenotypes (M1) (Mosser and Edwards, 2008). These 
macrophages are responsible for host protection against intracellular bacteria or viruses 
(Martinez, 2008; Wang et al., 2018). In comparison, alternatively activated macrophages (M2) 
are split into four sub populations. M2a macrophages are induced by IL-4 and IL-13 (Mantovani 
et al., 2004) and express high levels of the mannose receptor, IL-R and CCL17. Also named 
wound-healing macrophages they secret TGF-β, insulin-like growth factor and fibronectin 
allowing M2a macrophages to contribute to tissue repair. M2b macrophages are induced by 
combined exposure to immune complexes and TLR agonists or by IL-1R agonists (Mantovani 
et al., 2004). A primary feature of M2b macrophages is that they express and secrete large 
amounts of IL-10 (Anderson and Mosser, 2002; Yue et al., 2017) with these macrophages 
having a regulatory function. M2c macrophages (acquired deactivation macrophages) are 
induced by IL-10. These macrophages are primarily anti-inflammatory, accomplished by 
releasing large amounts of IL-10 and TGF-β (Mantovani et al., 2004; Rőszer, 2015). Lastly 
M2d macrophages are induced by co-stimulation with TLR ligands and the A2 adenosine 
receptor (Wang et al., 2010). M2d cells produce high levels of IL-10, TGF-β, vascular 
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endothelial growth factor, and contribute to the angiogenesis and cancer metastasis in neoplastic 
tissue (Ferrante and Leibovich, 2012). 
 
Interestingly research has shown that alveolar macrophages fall into neither category with a 
large proportion of resting alveolar macrophages expressing a duo M1/M2 phenotype (Mitsi et 
al., 2018; characteristics of M1 and M2 macrophages is shown in table 1), with alternate 
classification being suggested in 2008 (Mosser and Edwards, 2008). This proposed 
classification (shown in figure 1) is based on three fundamental macrophage functions involved 
in maintaining homeostasis: host defence, wound healing and immune regulation (Mosser and 
Edwards, 2008). This concept of nomenclature insists on being shades of activation which 
results in a spectrum of macrophage characteristics instead of two defined categories.  
 
 
Figure 1: Colour pin wall of macrophage characteristics. A depiction of the questionable nomenclature of the M1 
and M2 macrophage designations, followed by a pin wheel graphic. The pin wheel graphic suggests a spectrum of 
macrophage function, and that classically activated macrophages may also have many characteristics associated with 




Table 1: This table contrasts the characteristics of the two types of macrophages (Gordon, Plüddemann and 
Martinez Estrada, 2014). As mentioned previously this classification of macrophages should be seen as less 
definitive as macrophages have been observed to show a M1/M2 duo phenotype. 
 
M1 Macrophages M2 Macrophages 
Classically activated by IFN-γ or LPS. 
Alternatively activated by exposure to 
certain cytokines such as IL-4, IL-10, or IL-
13. 
Produce proinflammatory cytokines, 
phagocytize microbes, and initiate an 
immune response. 
Produce polyamines to induce proliferation, 
and proline to induce collagen production. 
Responsible for killing of intracellular 
pathogens. 
Associated with tissue repair and building 
the extracellular matrix. 
Responsible for tumour resistance. 
Responsible for encapsulation and killing of 
extracellular parasites. 
Require antigen presentation. Does not require antigen presentation. 
 
Macrophages have several effector functions including the ability to produce relatively large 
amounts of cytokines and chemokines involved in the immune response, commonly referred to 
as pro-inflammatory or anti-inflammatory cytokines (Arango Duque and Descoteaux, 2014). 
Cytokines are small proteins that are released from an activated macrophage where they can act 
on distant cells (endocrine) or in some instances act on themselves (autocrine) or nearby cells 
(paracrine; Arango Duque and Descoteaux, 2014).  Examples of cytokines produced by alveolar 
macrophages include: TNFα, a cytokine involved in systemic inflammation and is present in the 
acute phase (Idriss and Naismith, 2000); Granulocyte colony stimulating factor (G-CSF) known 
to induce differentiation of bone marrow stem cells to neutrophils and activate mature 
neutrophils (Roberts, 2005); IL-6, which in synergy with IL-4  and IL-13 enhances 
phosphorylation of M2 macrophages (Fernando et al., 2014); IL-12, a promotor of Th1 
responses and inducer of IFNγ production by T and NK cells (Arango Duque and Descoteaux, 
2014); IL-27, which amplifies cytokine production is response to gram negative bacteria (Petes 
et al., 2018); IL-1β, a cytokine vital in maintaining host response to infection and injury 
(Dinarello, 1996); CXCL1 a chemokine essential in neutrophil recruitment (Altmann et al., 
2012) and TGF-β, an anti-inflammatory cytokine involved in the resolution phase of tissue 
injury (Khalil et al., 1989). As alveolar macrophages are mostly pro-inflammatory cells it is 
possible to measure production of these cytokines as an assessment of their activity (Arango 





Macrophages play an essential role in phagocytosis which is the ingestion of large pathogens 
(>0.5µm) namely bacteria, dead cells or other material by phagocytes (Aderem and Underhill, 
1999), another key effector function. This is commonly mediated by pattern recognition 
receptors (PRRs) interacting with pathogen associated molecular patterns (PAMPs). Once inside 
the macrophage the pathogen is enclosed in a phagosome which fuses with a lysosome 
containing: enzymes, Reactive Oxygen Species and Reactive Nitrogen Species which digest the 
pathogen. Products of this process are either used by the macrophage or removed by exocytosis.  
 
Macrophages are also key mediators of efferocytosis, the process of engulfing and digesting 
dead, dying or stressed cells (Grabiec et al., 2018). This process ensures rapid clearance of dead 
cells preventing the release of DAMPS, which if not removed would be recognised by PRRs. 
This process is particularly important in alveolar macrophages to prevent excess neutrophil 
recruitment into the alveoli (Mahida and Thickett, 2018). 
 
1.2 Alveolar macrophages 
Residing in the alveolus of the lung, alveolar macrophages are the first line of the cellular 
immune response of the lung microenvironment (Mathie et al., 2014). It is due to their location 
that these macrophages are tasked with removing pathogens as well as harmful air pollutants 
which if not removed, would have a major impact in lung function (Sibille and Reynolds, 1990; 
Gonzalez et al., 2018). Alveolar macrophages can remove these toxic and infectious particles 
from the lung by secretion of oxygen metabolites, proteases and lysozymes coupled with 
processes such as phagocytosis (Rubins, 2003). When faced with large amounts of infectious 
particles these macrophages are able to produce a large variety of inflammatory cytokines and 
chemokines, which recruit other immune cells, such as neutrophils, to the area (Arango Duque 
and Descoteaux, 2014).  
 
Alveolar macrophages express both Axl and MERTK receptors linked to clearance of apoptotic 
cells (Grabiec et al., 2018). The requirement to efficiently remove apoptotic cells is particularly 
important to alveolar macrophages due to their highly inflammatory nature, which otherwise 
would induce secondary necrosis and the release of cellular components (Grabiec et al., 2018). 
Impaired clearance of apoptotic cells would cause accumulation of secondary necrotic cells 
prolonging inflammation, a possible cause of: Acute Respiratory Distress Syndrome (Mahida 







The diversity of surface receptors is a well-documented trait of macrophage tissue specificity 
that is associated with functional outcomes (Davies et al., 2013). Alveolar macrophages are able 
to act as sentinels of the respiratory mucosal surfaces (Mathie et al., 2014), maintain 
immunological homeostasis (Holt et al., 2008) and quickly respond to PAMPs such as LPS and 
peptidoglycan to become highly inflammatory. These characteristics are most likely the result of 
the high levels of CD68, CD11c, MARCO, TLR 2 and 4 which are expressed as the result of 
tissue adaptation, and are not present in such levels by macrophages from other sites (Davies et 
al., 2013). 
 
Alveolar macrophages are known to be highly inflammatory cells (He et al., 2016) capable of 
self-renewal (Tarling, Lin and Hsu, 1987; Zasłona et al., 2014). A possible reason for alveolar 
macrophages being described as highly inflammatory is because TLR4-LPS signalling increases 
the surface expression of IL-1RI (He et al., 2016). The upregulation of IL-1RI sensitises 
alveolar macrophages to IL-1β resulting in alveolar macrophage pyroptosis, exaggerating lung 
inflammation (He et al., 2016). 
 
However as alveolar macrophages reside in such a delicate tissue, their activation needs to be 
closely regulated by contact with epithelial cells (Hussell and Bell). Epithelial cells provide 
negative signals by expressing CD200, which binds to CD200R present on alveolar 
macrophages (Hatherley and Barclay, 2004; Snelgrove et al., 2008). Macrophages can also 
receive negative signals when exposed to anti-inflammatory cytokines produced by or tethered 
onto epithelial cells, such as TGF-β and IL-10 (Morris et al., 2003; figure 2). This negative 
signalling is essential, to avoid unnecessary or dysregulated inflammation. Excess inflammation 
will damage the delicate surrounding tissue leading to a loss of function (Knapp et al., 2003).  
 
Siglec-F is another alveolar macrophage cell surface receptor thought to be involved in alveolar 
macrophage negative regulation. However, there is only partial evidence to support this 





Figure 2: Alveolar macrophages close contact with the respiratory epithelium. This figure shows how Siglec-F 
binds to the respiratory epithelia (blue) as well as soluble glycoconjugates mucins (red; edited from Kiwamoto et al., 
2013; Hussell and Bell, 2014; Janssen et al., 2016). 
 
1.3 Alveolar macrophages in COPD  
COPD is an umbrella term for emphysema (damage to the alveoli) and bronchitis (long term 
inflammation of the bronchial tubes) both resulting in breathing difficulties as a result of airflow 
restriction which is not fully reversible (Vogelmeier et al., 2017). The primary trigger of COPD 
is inhalation of tobacco smoke caused by smoking (Eapen et al., 2017). Tobacco smoke is a 
mixture of solid and liquid particles and includes many well-characterised toxins and 
carcinogens (Smith and Fischer, 2001). Long term exposure to tobacco smoke can result in a 5-
10 fold increase in the number of alveolar macrophages, demonstrated in patients diagnosed 
with COPD (Tetley, 2002), with there being a direct correlation between macrophage number 
and COPD severity (Di Stefano et al., 1998). Alveolar macrophages are activated by the tobacco 
smoke and other irritants found in the smoke resulting in production of pro-inflammatory 
mediators increasing macrophage number (Davis et al., 1988; King, Savici and Campbell, 1988; 
van der Vaart et al., 2004). These activated alveolar macrophages secrete proteases leading to 
destruction of the lung parenchyma (Barnes, Shapiro and Pauwels, 2003). 
 
As a result of the high rate of inflammation, the antibacterial capabilities of alveolar 
macrophages are reduced and this explains why patients with COPD are more susceptible to 
bacterial infections (Monsó et al., 1995). These “low-quality macrophages” have impaired 
phagocytosis which allows for easier bacterial colonisation in the lung. Impaired efferocytosis is 
also a key factor in COPD (Hodge et al., 2007) as it results in continued recruitment of 
neutrophils further increasing the severity of bronchitis. A chronic effect of cigarette smoke is 
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the depletion of the GSH stores in the lung (Muller and Gebel, 1998), a major antioxidant 
leading to increased oxidative stress in alveolar macrophages.  
 
GM-CSF is a cytokine required for alveolar macrophage function and pulmonary homeostasis 
(Trapnell and Whitsett, 2002). The importance of this cytokine is demonstrated using GM-CSF 
knockout-mice where the activity and maturation of alveolar macrophages are impaired 
resulting in a phenotype similar to emphysema or pulmonary alveolar proteinosis (Stanley et al., 
1994). The impairment of alveolar macrophage maturation allows for infection with a wide 
range of opportunistic bacterial and fungal species (Stanley et al., 1994). GM-CSF knockout-
mice are characterised by an increased accumulation of lung surfactant when compared to 
alveoli in wildtype (Dranoff et al., 1994). This increased surfactant enlarges the alveolar 
structures resulting in a similar histology to emphysema (Yoshida and Whitsett, 2006). It is 
therefore evident that GM-CSF plays a critical role in the pulmonary homeostasis of alveolar 
macrophages (Dranoff et al., 1994). 
 
1.4 Alveolar macrophages in asthma 
Asthma is a syndrome in which the airways become chronically inflamed due to an overreaction 
to non-harmful allergens but can also result from irritant chemicals, cold and exercise (Martinez 
and Vercelli, 2013). The inflammation leads to thickening of the bronchi due to smooth muscle 
contraction and increased mucus production resulting in shortness of breath (Niimi et al., 2003; 
Dey and Bloom, 2004). 
 
Alveolar macrophages serve in the initial response after allergen exposure having an enhanced 
capacity for phagocytosis. In Asthmatics, alveolar macrophages promote the production of 
higher levels of the proinflammatory Th-2 cytokine and IL-5 by CD4 T-cells (Tang et al., 
1998), leading to enhanced recruitment of eosinophils and the pathology seen in eosinophilic 
asthma. Mathie et al (2014) showed, using a house dust mite mouse model of asthma, that 
depletion of alveolar macrophages with clodronate liposomes, increases IL-13 eosinophilic and 
Th-2 inflammation and reduces resolution in an IL-27-driven manner (Mathie et al., 2014). The 
data in this report might be partially confounded by an incomplete depletion of alveolar 
macrophages and the potential inflammatory response normally associated with clodronate 
treatment.    
 
Alveolar macrophages from asthmatic patients also demonstrate a higher rate of apoptosis as 
well as an impaired phagocytic ability (Fitzpatrick et al., 2008). Additionally, the epithelium of 
asthmatic patients produces greater levels of GM-CSF when compared to healthy controls 
(Sousa et al., 1993). Altogether, this data highlights the potential role of an allergic airway 
disease in altering the turnover of alveolar macrophages and their ability to remove pathogens 
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and particulates from the lung; possibly resulting in an altered microbial environment (Fricker 
and Gibson, 2017).  
 
Alveolar macrophages in asthmatic patients are also defective in efferocytosis, resulting in 
elevated levels of dead cells and DAMPs in the upper and lower airways (Simpson et al., 2012).  
This causes a continued state of activation of innate immune cells via PRRs binding to DAMPs, 
as well as a sustained production of proinflammatory cytokines such as TNF-α, IL-1β, IL-16 
and IL-18 (Ackerman et al., 1994).  
 
1.5 Siglec-F 
Siglecs are immunoglobulin -like cell-surface lectins that bind to glycoconjugates containing 
sialic acids as well as secreted glycoproteins. There are 14 different Siglec receptors in humans 
(Crocker, Paulson and Varki, 2007), expressed in varying amounts on immune cells, however 
they do exist on other mammals including mice where they follow a lettering system (Crocker, 
Paulson and Varki, 2007). 
 
Human Siglec-5 to 11 are CD33-related Siglecs, which can be identified by the ITIM and/or 
ITIM like motifs in their cytoplasmic domains. Thus, these Siglecs are thought to have a 
primarily regulatory role. In contrast, Siglec-4, 14, 15 and 16 do not have an ITIM or ITIM like 
motif, but instead signal through the association of DAP12 and are therefore called activating 
Siglecs. DAP12 associates with the ITAM present in the cytoplasmic tail of these activatory 
Siglecs resulting in PI3k recruitment (Angata et al., 2007). These functional characteristics are 
broadly conserved in both humans and mice (Crocker, Paulson and Varki, 2007). Siglec-F and 
its human paralog Siglec-8 are found on the cell surface of alveolar macrophages in the lung, 
where they act as regulators of the activity of these cells (Angata et al., 2006). It putatively does 
this by binding to the epithelial of the lung or soluble ligands in mucins and collectins (Janssen 
et al., 2016). 
 
Although the specific role of Siglec-F as a regulator of alveolar macrophage function is not fully 
understood (Feng and Mao, 2012), it has been shown to act as a negative regulator similar to 
TGF-β, CD200R and IL-10 (Morris et al., 2003). Potential outcomes of Siglec-F signalling 
could be an increase in transcription of genes already associated with negative regulatory 
pathways such as Smad7 in TGF-β signalling (Yan, Liu and Chen, 2009). 
 
In an in vivo environment, Siglec-F ligands are glycoconjugates containing sialic acids (Janssen 
et al., 2016). These molecules are long and complex and could be signalling other cell surface 
proteins simultaneously. Recent developments have shown that Siglecs can be more specifically 
targeted using crosslinked monoclonal antibodies specific for a Siglec receptor, thus mimicking 
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natural signalling (Zhang et al., 2007; Feng and Mao, 2012). This system has been previously 
established using flow cytometry but literature is yet to explore whether successfully targeting 
Siglec-F using monoclonal antibodies results in intracellular signalling. 
 
 
Table 2: This table contrasts Siglecs present on human cells with those found on mice cells (Crocker, Paulson 
and Varki, 2007). All known Siglecs can be divided into two groups according to their structure and presence of 
similar genes, portions of genes, or chromosome segments between different species. The CD33 related Siglecs often 
share similar extracellular structure and often contain tyrosine-based signalling motifs in their intracellular domains 
(Crocker, Paulson and Varki, 2007). This is displayed in Siglec-F (humans) and Siglec-8 (mice) where they are 
described as paralogs (Crocker, Paulson and Varki, 2007). The other group of Siglecs consisting of sialoadhesin, 
CD22, myelin-associated glycoprotein and Siglec-15 often have lower similarity in their structure between mammals 









Figure 3: The different Siglecs expressed in five types of human immune cells (edited from Lübbers et al., 2018). 
Shown with a blue background are monocytes and monocyte derived dendritic cells (moDCs) and monocyte derived 
macrophages (moMQ). Highlighted in red are types of dendritic cells that appear in peripheral blood and lastly in 
green are macrophages. Differences in microenvironment could lead to alternated Siglec expression.  
 
 
Figure 4: Artists impression of the Siglec-F receptor (Janssen et al., 2016). α2,3-sialic acid on the epithelium 
protein Muc5b, binds to the N-terminal lectin domain of the Siglec-F receptor. This drives ITIM and ITIM-like 
domain activation which recruit SHP enzymes that suppress kinase-activated inflammatory signals. 
 
The inhibitory function of Siglec-F is likely caused by the presence of ITIMs in the cytoplasmic 
tail of Siglec-F shown in figure 4 (Angata et al., 2006). ITIMs work by suppressing the 
activation signals that come from ITAMs, through recruitment of phosphates and tyrosine to the 
ITAMs (Khatua, Roy and Mandal, 2013). The signalling pathway of ITIMS is initiated by the 
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binding of a sialylated domain to the Siglec-F receptor; leading to phosphorylation of the ITIM 
in the cytoplasmic tail of the receptor by SRC-family tyrosine kinases (Tourdot et al., 2013). 
SHP1 and SHP2 protein then bind to the Siglec, becoming activated (Tourdot et al., 2013). This 
initiates several functional outcomes shown on figure 5. Recruitment of SHP-1 to Siglec-F 
would therefore be a way to confirm intracellular signalling. 
 
Figure 5: Proposed intracellular signalling pathway for CD33-related Siglecs. (edited from Crocker, Paulson and 
Varki, 2007). This figure shows the proposed intracellular pathway for ITIM, the intracellular signalling portion of 
CD33-related Siglecs. 
 
Recent evidence (Janssen et al., 2016) suggests that there are functional links between alveolar 
macrophage function and the mucus present in the airways. This is demonstrated by the large 
number of immunoglobulins and complement found in secreted mucus (Janssen et al., 2016), 
from this it can be hypothesised that mucus is an important carrier of these defensive molecules 
and that it allows for the immune response to spread faster. There are also links being made 
between secreted mucins and alveolar macrophages evident by their coordination when 
resolving inflammation and physical binding of mucins and Siglecs (Janssen et al., 2016). 
Interestingly, alveolar macrophages activated by inflammation decrease in their Siglec-F surface 
expression (Janssen et al., 2016), possibly due to there not being a need for negative regulation. 
Siglec-F expression increases during the resolution of inflammation alongside apoptosis 
(Janssen et al., 2016). 
 
1.6 The functional role of Siglec-F in alveolar macrophages 
The specific role of Siglec-F on alveolar macrophages is not fully understood, though Siglec-F 
is known to be expressed on the surface of eosinophils where the targeting of Siglec-F with 
crosslinking antibodies has been proposed to induce eosinophil apoptosis (O’Reilly and 
Paulson, 2009; Feng and Mao, 2012). This is not observed in alveolar macrophages. Instead, 
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when Siglec-F is crosslinked in alveolar macrophages alongside apoptotic cells the phagocytic 
activity of resting alveolar macrophages is not alerted (Feng and Mao, 2012). Despite this, the 
phagocytic activity of Siglec-F crosslinked alveolar macrophages is significantly lower when 
compared with peritoneal macrophages (Feng and Mao, 2012). Suggesting a suppressive role of 
alveolar macrophages. 
 
Lung macrophages have been proposed to be central in regulating type 2 responses (IL-4-
mediated; Van Dyken and Locksley, 2013), as IL-4 activation results in regulatory macrophages. 
Arg1 expressed on alternatively activated macrophages competes with enzyme inducible nitric 
oxide synthase (iNOS), an enzyme seen on the surface of M1 macrophages (Lowenstein and 
Padalko, 2004). However, there is new evidence to suggest that Siglec-F may not be involved in 
regulating type two hyporesponsiveness of alveolar macrophages in the lung (Svedberg et al., 
2019). When removed from the lung the type 2 hyporesponsiveness of alveolar macrophages is 
lost (Svedberg et al., 2019). Flow cytometry data can be used to measure the 
hyporesponsiveness of alveolar macrophages to IL-4, as mice injected with IL-4 show elevated 
expression of markers associated with IL-4: RELMα, Ki67 and EdU on the surface of alveolar 
macrophages (Jenkins et al., 2011; Svedberg et al., 2019). Alveolar macrophages that had been 
removed from the lung and rapidly expanded with IL-4 did not upregulate RELMα, Ki67 or 
EdU (Svedberg et al., 2019). This lack of response to IL-4 suggests that this response is 
regulated by the lung environment. Ki67 is a protein present in the nucleus during interphase 
and mitosis, but is absent when the cell is at rest, it is for this reason that Ki67 is used as 
proliferation marker (Scholzen and Gerdes, 2000). 
 
Mucin5b is the dominant pulmonary airway mucin present on the epithelial cells, the expression 
of which is increased after treatment with IL-4 in vivo (Svedberg et al., 2019), speculating that 
the two might be linked. However, comparison of gene profiles of wildtype mice to mucin5b 
knockout-mice showed similar gene profiles and little change in upregulation and 
downregulation of selected pathways from KEGG analysis (Svedberg et al., 2019). This lack of 
change suggests that mucin5b is not a dominating factor in hyporesponsiveness to IL-4 
(Svedberg et al., 2019). IL-4 hyporesponsiveness is therefore independent of Siglec-F 
interactions as mucin5b is the main source of sialylated ligands of this receptor. The regulation 
of IL-4 responsiveness is also seen to be independent of specific organisms present in the lung 
microbiome, as expression of RELMα and Ki67 was similar in germ-free and specific pathogen 
free mice after IL-4 administration (Svedberg et al., 2019). In contrast, very little is known 
about Siglec-F as a regulator of either type 1 (IFNγ-mediated) or general pathogen associated 




1.7 Hypothesis  
The specific effector functions of Siglec-F on the surface of alveolar macrophages is currently 
not fully understood, although it is suspected to act as a negative regulator of alveolar 
macrophage function and adaption. It is hypothesised that Siglec-F crosslinking would induce 
changes in the gene expression programme of these cells. Analysis of gene ontology and 
cytokine production could give a greater understanding into the mechanism of how Siglec-F 
acts as a negative regulator of alveolar macrophage function and adaptation.  
Targeting and modulating this pathway could uncover new therapeutic targets or biomarkers for 
diagnosis and treatments in disease such as Asthma and COPD where alveolar macrophages 
play a key role as sentinel cells with regulatory activity.  
 
1.8 Aims 
The overarching aim of this project is to investigate the outcome of signalling through Siglec-F 
in mouse alveolar macrophage by whole genome expression and cytokine production. To do 
this, a highly specific antibody crosslinking system previously established using flow cytometry 
will be used to specifically target Siglec-F.  
 
1.9 Objectives 
The following are objectives for this project together with the experiments that will be used to 
complete them: 
 
- To ascertain proof of signalling through Siglec-F by measuring recruitment of SHP-1 
by Western blot. 
 
- To determine the most suitable timepoint for collection of macrophages from the 
stimulation cultures, by measuring cell death and the ability to produce cytokines. For 
use in RNA-seq experiments.  
 
- To analyse changes in gene expression associated with the Siglec-F signalling pathway, 
using RNA-seq, to identify gene targets and alterations in functional or differentiation 
pathways.  
 
- To characterise a primary cell-line based system of foetal liver-derived alveolar 





1.10 Significance and project impact 
Asthma has been identified as one of the major non-communicable diseases, with an estimated 
235 million people suffering from the disease worldwide with 383,000 dying from the disease in 
2015 (World Health Organisation, 2017). Research into alternative therapeutic techniques has 
been a priority for Asthma UK, a member-based charity who reported that in 2015 5.4 million 
people in the UK suffer from the disease, with 70,888 of these asthmatics requiring emergency 
hospital aid (Asthma UK, 2018). A potential biomarker for the diagnosis of asthma is the 
significant increase in CCL17 mRNA produced by alternatively activated (M2) macrophages 
(Staples et al., 2012). M2 macrophages have been shown to regulate Th-2 responses in asthma 
(Girodet et al., 2016). A possible treatment for asthma could therefore be reprogramming 
alveolar macrophages towards an alternatively activated lineage, where Siglec-F could then be 
utilised to keep the macrophage bound to the lung epithelia. RNA-seq experiments could 
provide information on how to manipulate the negative signalling as an alternative way of 
inactivating the macrophage.  
 
In COPD there is a marked increase of alveolar macrophages in the lung (Pesci et al., 1998) 
with a positive correlation between number of alveolar macrophages and COPD severity (Di 
Stefano et al., 1998). As alveolar macrophages produce neutrophil chemotactic factors, 
neutrophils produce proteases which breakdown lung connective tissue, resulting in COPD. A 
biomarker for COPD could therefore be the large increase in IL-8 and LTB4. Possible 
treatments for COPD are anticholinergic drugs such as tiotropium bromide which have been 
proposed to have anti-inflammatory effects (Barnes and Stockley, 2005). From RNA-seq 
experiments it could also be possible to pair anticholinergic drugs with Siglec-F stimulants to 








Inbred, C57BL/6J females of 6-10 weeks of age were purchased from Envigo UK.  
 
Bronchoalveolar lavage 
● RPMI media was purchased from Gibco. 
● Red-blood cell lysis buffer (ACK) was purchased from Thermofisher. 
● Trypan blue 0.4% solution was purchased from Lonza group. 
● Versene was purchased from Gibco. 
 
Naïve Peritoneal Lavage  
● PBS pH: 7.2 was purchased from Gibco. 
● Red-blood cell lysis buffer. 
 
Dynabeads immunoprecipitation  
● Dynabeads suspended commercial buffer purchased from Thermofisher. 
● Antibody binding and washing buffer Purchased from Thermofisher. 
● Washing buffer purchased from Thermofisher. 
● Elution buffer purchased from Thermofisher. 
● NuPage LDS sample buffer from Thermofisher. 
● Lysis buffer purchased from Thermofisher. 
● Dynamag magnet purchased from Thermofisher. 
 
Western blot experiments 
● Versene was purchased from Gibco. 
● LPS (at a concentration of 0.5mg/ml) was purchased from Sigma-Aldrich. 
● SDS-PAGE Gel purchased from Thermofisher. 
● Page ruler+ purchased from Thermofisher. 
● Transfer buffer (0.025M Tris, 0.192M glycine, pH 8.5) was purchased from Thermofisher.  
● Running buffer (50 mM MES, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.3) was 
purchased from Thermofisher.  
● Blocking buffer (PBS 5% skimmed milk) was purchased from Thermofisher. 
● Whatman paper was purchased from Sigma-Aldrich. 
● PVDF paper purchased from Thermofisher. 
● Methanol was purchased from Sigma-Aldrich. 
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● Peroxide solution purchased from Thermofisher. 
● Luminol enhancer solution purchased from Thermofisher. 
 
Cell culture of FLDAM and AM  
● Penicillin/streptomycin was purchased from Thermofisher. 
● L-Glutamine was purchased from Thermofisher. 
● Complete RPMI (RPMI media 10% FCS 20 mM glutamine, 1000U/ml penicillin) was 
purchased from Thermofisher. 
● G-CSF (0.2mg/mL) was purchased from BioLegend. 
● Trypan blue 0.4% solution was purchased from Lonza group. 
● Foetal calf serum was purchased from Gibco. 
 
Generation of BMDM 
● Mice (inbred, females C57BL/6J). 
● Conditioned media (containing 30% M-CSF from transduced L929 cells) was purchased from 
Thermofisher. 
● Ethanol was purchased from Sigma-Aldrich. 
 
● PBS pH: 7.2 was purchased from Gibco. 
 
ELISA 
● TNF-α ELISA Kit Purchased from BioLegend (cat: 430907). 
● FACS buffer: PBS 10% FCS 0.1% sodium azide was generated at the university. 
 
Materials for LEGENDplex experiments 
● LEGENDplex mouse macrophage/microglia panel 8-plex (CXCL1, IL-1β, IL-23, IL-12p70, 
IL-12p40, IL-6, TNF-α, and TGF-β1) + G-CSF kit purchased from BioLegend. 
 
RNA extraction 
● Picopure RNA extraction kit was purchased from Thermofisher. (cat: KIT0204) 
 
RNA-seq 
● RNA sequencing will be performed using the illumina NextSeq 500 platform and services 








Table 3: The table below contains the details for non-conjugated antibodies used throughout this MRes. 
Supplier Catalogue 
Number 
Specificity Isotype     Dilution Application 
BD Biosciences 552125 Mouse  
Siglec-F 
Rat IgG2a 1:100 Crosslinking 
BD Biosciences 553926  Isotype Control Rat IgG2a 1:100 Crosslinking  
Biolegend 553926 Rat IgG   Goat IgG 1:100 Crosslinking 
        Biolegend                      101319 Mouse 
CD16/32 
Rat IgG2a  1:100 Flow 
cytometry 




Table 4: This table contains the details for fluorochrome conjugated rat anti mouse antibodies used 
throughout this MRes, all purchased from Biolegend. 
Catalogue number Specificity Attached 
Fluorochrome 
Clone 
123907 CD200r PE OX-110 
151507 MERTK APC 2Bioc42 
155505 Siglec-F PE S17007L 
123147 F4/80 BV711 BM8 
137005 CD68 FITC FA-11 
101207 CD11b PE M1/70 
117313 CD11c Alexa Fluor N418 
652403 Ki-67 PE 16A8 





Table 5: This table contains the enzyme-conjugated antibodies used throughout this MRes. 
Supplier Catalogue 
number 
Specificity Isotype Attached Enzyme 





In this project a Siglec-F antibody crosslinking system, established in previous experiments, has 
been used to signal through the Siglec-F receptor.  
 
The system is depicted in figure 6 and involves the binding of cell surface Siglec-F by a highly 
specific anti mouse Siglec-F monoclonal antibody. It is hypothesised that signalling will be 
induced when two Siglec-F receptors are brought together by the specific binding of the Fc 
portion of these monoclonal antibodies by a secondary anti rat IgG monoclonal antibody.  
 
 
Figure 6: Anti-Siglec-F antibody crosslinking system. This figure shows how crosslinking using anti-Siglec-F 
antibodies (left) and the isotype control (right) works. 
 
2.2.1 Extraction of alveolar macrophages from mice  
Mice are killed by cervical dislocation (at UEL) or lethal pentobarbital injection (100mg/Kg; at 
UCL). Scissors were then used to remove skin, create a lung pneumothorax and remove the 
peritracheal membrane to make the trachea accessible. Using a scalpel an incision was made in 
the trachea allowing for the tip of a venous catheter to be inserted which was used to flush the 
lungs with RPMI media (+0.1% EDTA); this was done to collect the alveolar macrophages. 
This process was repeated twice for each mouse. 
 
The pooled contents of the bronchoalveolar lavage (BAL) was spun at 350 RCF for 5 minutes 
after which the supernatant was discarded. When necessary, the pellet was resuspended in 5mL 
of ACK (a red blood cell lysis buffer) for 30 minutes in to order to rupture any red blood cells. 
Five millilitres of RPMI media was then added to the sample to neutralise the ACK. The sample 
was then spun at 350 RCF for 5 minutes after which the supernatant was removed and the 
sample resuspended in complete RPMI for further use. Cell numbers were estimated using 





2.2.2 Extraction of peritoneal cavity cells 
Mice were killed by cervical dislocation or lethal pentobarbital injection (100mg/Kg). Scissors 
were then used to cut the outer skin of the peritoneum and gently pull it back to expose the inner 
skin lining the peritoneal cavity. Cold PBS was then injected into the peritoneal cavity being 
careful not to puncture surrounding organs. A syringe was then used to collect the maximum 
volume of fluid which was then deposited into a centrifuge tube kept on ice. For maximum yield 
insertion of PBS was repeated at least once per mouse.  
 
After all the mice had undergone this process the contents of the peritoneal cavity in PBS media 
was spun at 350 RCF for 8 minutes after which the supernatant is discarded. When necessary, 
the pellet was resuspended in 5mL of ACK for 30 minutes in to order to rupture any red blood 
cells present. Five mL of PBS media was then added to neutralise the ACK. The sample was 
then spun at 350 RCF for 5 minutes after which supernatant was removed and the sample 
resuspended in PBS. Number of cells was then estimated using trypan blue exclusion. 
Peritoneal cavity cells were used to compare the expression of macrophage marker F480 and 
alveolar macrophage marker Siglec-F with alveolar macrophages using a C6 Accuri flow 
cytometer. 
 
2.2.3 Differentiation of macrophages from mouse bone marrow using M-CSF  
Mice were killed by cervical dislocation or lethal pentobarbital injection (100mg/Kg). The 
abdomen and hind legs were then sterilised using 70% ethanol. An incision was made in the 
midline of the abdomen outwards, which exposed the legs. Scissors were then used to remove 
all muscle from the bone after which the bones are cut at both ends to free them. The femur was 
separated from the tibia by cutting at the knee joint before flushing the bone marrow with ice-
cold PBS from both bones. The cell suspension was then passed through a cell strainer (70µm) 
with the strainer being washed afterwards with lymphocyte medium to ensure maximum yield. 
Once all bone marrow cells have been harvested the cell suspension was spun at 350 RCF for 5 
minutes, with the pellet then being resuspended in conditioned media (with M-CSF-transduced 
L929 cells). A haemocytometer was then used to count the cells with a minimum of 7x106 cells 
being incubated in a culture plate with conditioned media. Culture was then incubated at 37oc 
with 5% CO2. After 7 days the culture was split (1/2) with fresh conditioned medium. Cells 
were used for experimental analysis when percentage of CD11b+ cells is higher than 90% as 
measured by FACS analysis (Zanoni, Ostuni and Granucci, 2009). Bone marrow derived 
macrophages were used to compare expression of macrophage marker F480 and alveolar 





2.2.4 Culturing FLDAM 
Mice foetal liver cells, acquired from the embryos of C56BL/6 mice 18 days post fertilisation, 
were added to RPMI with G-CSF (50ng/mL; Fejer et al., 2013). The mixture was then added to 
a cell culture flask and incubated at 37oc and 5% CO2 for a minimum of 14 days. During the 14 
days fresh RPMI and G-CSF were added where appropriate. After the 14 days cells were 
removed using a cell scraper, the cells were then spun at 350 RCF for 5 minutes and 
resuspended in RPMI. 10µl of cell suspension was then added to an equal volume of trypan 
blue, this mixture was placed underneath a cover slide on a haemocytometer. Using a 
microscope, the number of non-blue cells was counted in the four corner squares, to get cell 
number per mL the numbers are averaged and multiplied by 20,000. 
 
To continue cell culture G-CSF was added to the culture (50ng/mL) and placed back in a cell 
culture flask in an incubator. If cell number is >1,000,000 the culture was split between two cell 
culture flasks.  
 
2.2.5 Cell staining using fluorescently conjugated antibodies 
Samples (including: alveolar macrophages, peritoneal cells or derived macrophages) were spun 
at 350 RCF for 5 minutes, following either BAL, NPL or successful generation of BMDAM, 
after which supernatant is discarded. The pellet was then resuspended in FACS buffer with 
CD16/32 antibody in order to block Fc receptors and placed on ice for 10 minutes. Relevant 
conjugated antibodies were then added to stain specific cell surface receptors. The sample was 
left to stain in the dark for an hour. Excess antibody was removed by washing with FACS buffer 
with the pellet being resuspended in FACS buffer. Samples were analysed using a C6 Accuri 
flow cytometer.  
 
2.2.6 Using dynabeads for crosslinking Siglec-F antibodies and for immunoprecipitation 
 
Removing the cells from culture and continuing culture 
Macrophages used for these experiments were grown in sterile conditions (37oc, 5% CO2) in 
5ml complete RPMI and without activation. At least 500,000 were used for each experiment. 
 
A sterile cell scraper was used to remove the cells from the culture plates and cells were then 
pipetted into a centrifuge tube, which was spun at 350 RCF for 5 minutes. The pellet was 
resuspended in 3mL RPMI media. Cell number was estimated using trypan blue. This estimate 
is used to calculate the correct volume needed to successfully continue the culture. The 




Preparing beads and binding antibody  
Dynabeads were resuspended by vortexing after which 50µL was pipetted into each Eppendorf. 
All Eppendorf tubes were placed on the magnet to separate beads from solution and remove 
supernatant. Eppendorf tubes were then removed from the magnet. 10µL of the relevant 
antibody dissolved in 200µl of washing and binding buffer was added to each Eppendorf and 
incubated at room temperature with vortexing for 10 minutes. Eppendorf tubes were then placed 
on the magnet and supernatant was discarded after which the Eppendorf tubes were removed 
from the magnet. The beads were resuspended in 200µL binding and washing and washed by 
gentle pipetting.  
 
Immunoprecipitation and lysing of Siglec-F and isotype control  
Eppendorf tubes were placed on the magnet and supernatant is discarded after which the 
Eppendorf tubes are removed from the magnet. Approx. 1 million cells were added to each 
Eppendorf tubes and incubated with rotation for 10 minutes. The Eppendorf tubes are placed on 
the magnet and supernatants removed, after which the Eppendorf tubes were removed from the 
magnet and resuspended in washing buffer (this is repeated three times). After the final wash the 
pellet was resuspended in lysis buffer and incubated on ice for 30 minutes. Eppendorf tubes 
were then placed on the magnet, where the supernatants were removed and the Eppendorf tubes 
were taken away from the magnet; resuspended in PBS and left on ice. 
 
Immunoprecipitation and lysing of unstimulated cells 
The remaining cells (approx. 1 million cells) were lysed in lysis buffer for 10 minutes on ice, 
after which the sample was then spun at 13,793 RCF for 10 minutes. The supernatant was 
carefully pipetted into the Eppendorf containing the beads and the Siglec-F antibody (see 
preparing beads and binding antibody). The sample was then incubated on ice for 10 minutes. 
This Eppendorf was then placed on the magnet, where the supernatant was then removed after 





Figure 7: Artist’s impression of the anti-Siglec-F antibody Dynabeads crosslinking system. This figure shows 
how crosslinking using anti-Siglec-F antibodies (left) and the isotype control (right) works, when using anti IgG 
secondary antibodies bound to magnetic Dynabeads. 
 
Eluting the antigen 
All Eppendorf tubes were placed on the magnet where the supernatant was then removed after 
which the Eppendorf was taken away from the magnet and resuspended in 20µL Elution buffer 
and 10µL NuPage LDS sample buffer. In order to resuspend, the contents of the Eppendorf 
tubes were gently pipetted. The samples were then heated for 10 minutes at 70oc. 
 
Removing the DNA from isotype control and Siglec-F Eppendorf tubes  
Eppendorf tubes Siglec-F and isotype control were spun at 13,793 RCF for 5 minutes, 
afterwards the supernatant was carefully removed and pipetted into separate Eppendorf tubes. 
 
2.2.7 Western blot 
 
Samples 




To prepare the samples for Western blot 25µL of the sample (approx.: 5x105 cells), 25µL Tris-
glycine SDS sample buffer and 10µL 2-ME were pipetted into a labelled Eppendorf tube. The 
Eppendorf was then placed on a heat block at 100°C for 5 mins. In order to prevent gas build up 
a small incision was made at the top of the Eppendorf. Running buffer was poured into the tank. 
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The pre-prepared gel was gently taken out of the packet and the comb removed, running buffer 
was then used to wash wells. After washing the white tape was removed and gel placed into the 
tank. The gel was then locked in place and the tank topped up with running buffer so that wells 
were fully submerged before loading. 
 
25µL of each sample present was placed into individual wells and 10µL of ladder in the relevant 
well. For the empty columns 10µL of sample buffer was added, the lid was then secured, and 
the gel electrophoresis ran at 100v for 1 hour.  
 
Transfer  
The running buffer was discarded, and tank washed with distilled water. The gel was then 
removed from the case and placed into a large dish containing transfer buffer. 
 
In order to transfer the contents of the gel to a blot, 2 blotting papers were soaked in the transfer 
buffer alongside 2 black sponges. A sheet of PVDF similar size to the gel was soaked in 
methanol. The following configuration is then prepared inside the cassette black side down: the 
sponge, paper, gel, PVDF. It is at this stage that any air bubbles between the gel and PVFD 
were removed. The second filter paper was then placed on top of the PVFD and lastly the black 
sponge. The cassette was then locked.  
 
Running transfer and blotting 
 
An ice pack was placed inside the transfer tank followed by the cassette with black side of the 
cassette facing the black side of the tank. The tank was then filled with running buffer and ran at 
100v for 1 hour. After running PVDF paper was removed and soaked in blocking buffer for 1 
hour at room temperature. This step helps reduce non-specific primary antibody binding and 
reduces background.  
 
The membrane was then incubated with SHP-1 primary antibody (1:1000) overnight at 4°C. 
After which the membrane was washed 3 times with 0.05% tween 20/ PBS. The membrane was 
allowed to soak for 10-15 minutes each time. The membrane was then incubated with anti-goat 
TrueBlot IgG HRP (1:1000) in blocking buffer at room temperature for 1 hour. After which the 
membrane was washed 3 times with 0.05% tween 20/ PBS. With the membrane being allowed 
to soak for 10-15 minutes each time. Four millilitres of fresh substrate were then prepared by 
mixing peroxide solution and luminol enhancer (1:1). The membrane was then incubated with 




2.2.8 Apoptosis assay 
 
Approx. 1 million alveolar macrophages in RPMI media was added to 8 individual wells, with 
two of these wells containing LPS at a concentration of 10ng/mL, anti-Siglec-F antibody at a 
concentration of 1:100 being added to two of the wells, isotype control antibody at a 
concentration of 1:100 being added to two wells and lastly the remaining two wells were left 
unstimulated. To successfully crosslink anti-IgG antibody was added to the Siglec-F and isotype 
control wells at a concentration of 1:100. The 96 well plate was then incubated at 37oC and 5% 
CO2 for 18 hours. 
 
After incubation the well was removed from the incubator and supernatant was carefully 
removed and pipetted into labelled Eppendorf tubes and placed into the -20oC freezer for use in 
the TNF experiment. To detach the macrophages from the bottom of the well plate versene was 
added to each well, after which the plate was stored in the fridge for 30 minutes to further 
dislodge cells from the bottom of the well. To dislodge maximum number of cells each well was 
pipetted up and down before being pipetted into separate labelled Eppendorf tubes. To minimise 
background CD16/32 was added to each Eppendorf at a concentration of 1:100 and was left on 
ice for 5 minutes. 50µL annexin V (diluted in FACS buffer 1:100) was then added to each 
Eppendorf and left to stain on ice for 25 minutes in the dark. 
 
To remove excess annexin V all Eppendorf tubes were spun at 350 RCF for 5 minutes with the 
pellet then being resuspended in FACS buffer. To further remove background all Eppendorf 
tubes were washed twice. Eppendorf tubes were run on a C6 flow cytometer. 
 
2.2.9 Cytokine production: TNF ELISA 
 
The well plate 
The well plate was constructed by adding 100µL of diluted capture antibody (in assay diluent; 
1:200) to 48 wells, with the plate then being incubated overnight in a fridge (2-8oc) to maximise 
capture antibody binding to the well. After refrigeration the plate was allowed to rise to room 
temperature after which each of the 48 wells was washed with wash buffer four times to remove 
excess capture antibody. After washing 200µL assay diluent was added to each well, the plate 
was then sealed and incubated for an hour at room temperature with shaking. Each well was 
then washed four times with wash buffer. 150µL of each sample was added to two separate 
wells alongside a serial dilution with the TNF standard (1:2). The plate was then sealed and 
incubated at room temperature for an hour with shaking. 
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Each well was then washed with wash buffer. 100µL diluted detection antibody (in assay 
diluent; 1:200) was added to all 48 wells and the plate incubated at room temperature for an 
hour with shaking. Each well is then washed with washing buffer four times. 100µL of diluted 
Avidin-HRP (in assay diluent; 1:1000) is added to each of the 48 wells and plate incubated at 
room temperature with shaking for 1 hour. The plate was then washed with washing buffer five 
times with 5-minute intervals between washing, allowing the wells to soak. 100µL of TMB 
solution was then added to each well, the plate was then incubated in the dark for 30 minutes or 
until a blue colour developed. To stop the reaction, 100µL of stop solution was added to each 
well, turning the wells yellow. 
The absorbance of each well was then read at 450nm within 15 minutes of adding the stop 
solution using a Synergy HTX Multi-Mode Reader. A calibration curve of standards was then 
used to find TNF-α concentration (pg/mL).  
 
2.2.10 Cytokine production: multiplex cytokine bead array 
 
25µL assay buffer and 25µL sample/standard was added to the relevant wells, with standard 
wells undergoing a serial dilution of 1:4. For this experiment beads were used instead of IgG 
antibodies though the beads needed to be diluted by 13x in assay diluent, with an extra 20% 
being prepared to account for loss. The bead cocktail was vortexed for 10 seconds with 25µL 
being added to each well.  The plate was then sealed and covered with aluminium foil to protect 
from light and shaken at 140 RCF for 2 hours. 
 
After shaking, the plate was spun 240 RCF for 5 minutes. The supernatant was removed, and 
the pellet resuspended in wash buffer, the plate was then left to incubate for 1 minute. The plate 
was spun again at 240 RCF for 5 minutes. The pellets were then resuspended in 25µL of 
detection antibody, with the plate then being sealed and covered with aluminium foil and shaken 
at 140 RCF for 1 hour. Without washing 25ul of SA-PE was added to each well and plate sealed 
and covered with aluminium foil, the plate was then shaken at 140 RCF for 30min. After which 
the plate was spun at 240 RCF for 5 minutes. The pellet was resuspended in wash buffer in each 
well and left for one minute, after which the plate was spun at 240 RCF for 5 minutes with 









2.2.11 RNA sequencing 
 
RNA sequencing was carried out as described (Solanki et al., 2017). Alveolar macrophages 
were extracted from female C57BL/6J mice acquired via BAL with an estimated 95% purity. 
Alveolar macrophages were incubated in culture with RPMI with either IgG antibody 
crosslinked anti-Siglec-F antibody, IgG antibody crosslinked isotype antibody or without 
antibody (unstimulated) for 18 hours. RNA was then extracted using Arcturus PicoPure RNA 
Isolation kit with the quantity and quality determined by Bioanalyser 2100 (Agilent). RNA was 
also extracted from a population of macrophages immediately after BAL.  Extracted RNA was 
sequenced by UCL Genomics on the Illumina Next Seq 500. Genomic alignment was carried 
out by the UCL Genomics teams using STAR v2.5b. The RNA sequencing dataset was 
processed and standardised using the Bioconductor package DESeq2, which was used to 
generate normalised estimates of transcript abundance. Data analysis was carried out as 
described (Sahni et al., 2015; Solanki et al., 2017). PCA was performed using normalised 
transcript expression values, using the built-in R function for PCA. Graphical representations of 






3.1 Comparative analysis of Siglec-F expression between different types of macrophages 
Alveolar macrophages are known to express Siglec-F (Feng and Mao, 2012; Svedberg et al., 
2019) however, the levels of expression of this receptor between alveolar macrophages and 
other tissue residents or haematopoietic subsets has not been directly compared.  
Resting, non-elicited peritoneal macrophages and alveolar macrophages are two subsets of 
tissue-resident myeloid cells that differ largely in function and morphology (Guth et al., 2009). 
Bone marrow-derived macrophages (BMDM), differentiated in the presence of M-CSF, are 
commonly used as an in vitro model in macrophage biology and are considered a good 
approximation to study the phenotype and function of resting macrophages (M0).  Flow 
cytometry was used in order to compare the levels of expression of Siglec-F between these 
populations, and also to determine if the expression of this receptor is restricted to a particular 
population. Furthermore, the selection of an additional Siglec-F positive population would allow 
for use of multiple macrophage populations for further analysis. This is important as the 
extraction of alveolar macrophages from mouse lungs yields relatively low cell numbers, 
limiting downstream experimental work.  
Figure 8 shows representative data of the level of expression of Siglec-F in the above-
mentioned macrophages. These results showed that 72% of macrophages isolated by BAL 
expressed Siglec-F (reproduced in figure 9) at resting state, whereas less than 3% of BMDMs 
and peritoneal macrophages expressed the receptor. The comparatively high and restricted level 
of expression of Siglec-F could be a defining characteristic of alveolar macrophages as they 
adapt to the lung microenvironment. 
 
3.2 F4/80 + CD11c+ cells express receptors akin of an M1 phenotype 
In order to have an approximate assessment of the resting naïve alveolar macrophage 
differentiation phenotype (M1 or M2), resident macrophages were extracted from residual 
resting lung tissue. Lung cells were stained for the macrophage specific markers F4/80 and 
CD11c (highly expressed by alveolar macrophages) together with two characteristic phenotypic 
markers CD38 (M1) and Arg1 (M2). The results in figure 10 show that the vast majority of 
alveolar macrophages (92.1%) express the M1 macrophage receptor CD38 and not Arg1, 
interestingly the second largest population of alveolar macrophages express both M1 and M2 






After assessing the expression of cell surface receptors consistent with the functional 
phenotypes of macrophages; the level of expression of Siglec-F in each subset was assessed. 
Figure 12 shows that the expression of Siglec-F is high with 80.8% of CD38+ cells expressing 
the receptor and 81.8% of the CD38+Arg1+ cells also expressing Siglec-F. From this data it was 
concluded that Siglec-F expression does not segregate between airway macrophage subsets with 




Figure 8: Flow cytometry analysis of three different types of macrophages in mice. Cells shown were isolated 
via mice BAL (8a), mice NPL (8b) or from bone marrow of mice femurs (8c). The BMDM shown in 8c were 95% 
F4/80+ after one week in MCSF. Cell populations were then gated from the FSC vs. SSC dot plot to have the size and 
complexity of living macrophages. Cells were further gated for Siglec-F and F4/80 expression as these are markers 





Figure 9: A high proportion of F4/80+ alveolar macrophages express Siglec-F. This bar chart displays the 
percentage of Siglec-F positive and negative cells obtained via BAL in figure 8a. Bar chart shows the mean +/- SD of 
three independent experiments. 
 
 
Figure 10: Macrophages in the lung selectivity express CD38 when at rest. In 10a cells were acquired from 
resting lung tissue, and macrophage population identified on the basis of F4/80 and CD11c expression. 10b shows the 
percentages of F4/80+ CD11c+ macrophages that are positive or negative for CD38 and Arg1. Data representative of 






Figure 11: Graphical representation of alveolar macrophages from Q1 and Q2 from figure 10. Bar chart shows 
the average percentage (n=3) of F4/80+ CD11c+ lung cells, that are either CD38+ or CD38+Arg1+.   
 
 
Figure 12: Siglec-F expression by M1 and M2 lung macrophages. Flow cytometry histograms show the 
percentage of Siglec-F positive CD11c+CD38+Arg1- cells (12a) and CD11c+CD38+Arg1+ cells (12b). Blue 
overplayed histograms correspond to unstained background controls. Data is representative of three independent 
experiments. 
 
Figure 13: Graphical representation of Siglec-F+ alveolar macrophages from histograms shown in figure 12. 




3.3 Assessment of Siglec-F engagement using antibody crosslinking 
The aim of this project is to investigate the outcome of signalling through Siglec-F using a 
highly specific antibody crosslinking system (see figure 6 in methods), to assess changes in 
gene and protein (cytokine) expression. Flow cytometry was used to establish the extent of 
Siglec-F receptor targeting by performing a FACS stain using a PE-conjugated anti-Siglec-F 
antibody on cells. These cells have been previously crosslinked or treated with an isotype 
control as well as secondary antibodies.    
Using flow cytometry, an average percentage shift of 63% in MFI was observed when 
comparing Siglec-F crosslinked and the isotype control. This is equivalent to 63% of the Siglec-
F receptors being targeted by Siglec-F crosslinking. It is important to mention that although 
arbitrary, this method of exogenous ligand-independent signalling aims to avoid the saturation 
of all of the Siglec-F receptors on the surface of the cell as this could produce an 
unphysiological signal transduction strength. 
 
 
Figure 14: A proportion of Siglec-F receptors can be successfully targeted using antibody crosslinking. 
Alveolar macrophages were acquired via BAL. F4/80+ macrophages were treated with an unconjugated anti-Siglec-
F, or isotype control and an anti IgG secondary antibody prior to FACS staining with a PE-conjugated anti-Siglec-F 
antibody. The FACS histograms represent the extent of the loss of staining due to crosslinking and was measured by 
mean fluorescence intensity (MFI). The blue histogram represents the negative unstained background control, the 
black open histogram represents cells that have been “crosslinked” with an isotype and the red histogram represents 
cells that were crosslinked with anti-Siglec-F antibodies. The representative % targeting shown on the plot was 
estimated as the proportional difference in MFI between isotype-treated (representative MFI 12912) and Siglec-F 




3.4 Alveolar macrophages undergo minimal levels of apoptosis 18 hours after Siglec-F 
crosslinking  
It has been established that Siglec-F is a negative regulator of eosinophil activation in vivo 
(O’Reilly and Paulson, 2009). However, when targeted with anti-Siglec-8 antibodies in the 
presence of secondary antibodies, eosinophils undergo apoptosis due to signalling through a 
caspase-dependent pathway (Nutku, 2003).  As Siglec-F has been documented as a functional 
paralog of Siglec-8 (Angata et al., 2006) it is essential to see if this process happens when 
targeting Siglec-F in mice alveolar macrophages. To test this, alveolar macrophages were 
crosslinked between 18 and 24 hours. These time points are consistent with the crosslinking 
times considered for the RNA-seq experiments. After the above-mentioned time points, early 
apoptosis events were measured by assessing the translocation of phosphatidylserine Annexin 
V. 
 
Data in figure 15 shows that crosslinking Siglec-F on alveolar macrophages does not induce 
apoptosis like in eosinophils as the translocation of phosphatidylserine in the Siglec-F and 
isotype treated cells are comparable. Siglec-F crosslinking also induces similar levels of 
apoptosis to that seen in unstimulated macrophages both at 18 and 24 hours. Cell death does 
occur minimally at 18 hours, but is greater at 24 hours. For this reason, 18 hours was used as a 









Figure 15: Crosslinking Siglec-F receptors using antibodies does not result in self-apoptosis. Mouse alveolar 
macrophages isolated by BAL had their Siglec-F receptors crosslinked using antibodies for 18 hours and 24 hours. 
Cells were gated on an FSC vs. SSC and F4/80 plots (not shown) then displayed on a dot plot for CD11c vs Annexin 
V. A positive control was created by incubating with LPS at 50ng/mL with a negative control being alveolar 






3.5 Antibody crosslinking causes SHP-1 recruitment 
From previous experiments involving flow cytometry it was concluded that Siglec-F 
crosslinking was successful in targeting of the Siglec-F receptor, though it does not give 
evidence that antibody crosslinking results in intracellular signal transduction. To test this, 
resting naïve alveolar macrophages were crosslinked with anti-Siglec-F antibodies, treated with 
isotype antibodies or left unstimulated for 18 hours. Magnetic beads were used to 
immunoprecipitate and signal Siglec-F by acting as a secondary antibody. As a negative 
signalling control, unstimulated cells were lysed and later their Siglec-F receptor 
immunoprecipitated. The blot was then stained for presence of SHP-1 as this protein should 
have been recruited to the intracellular domain of Siglec-F during crosslinking (Tourdot et al., 
2013).  
 
Results showed a band near 70kDa (68kDa for SHP-1) in samples where alveolar macrophages 
had been crosslinked with anti-Siglec-F antibodies. This suggests the antibody crosslinking is 
successful in recruiting SHP-1 to the intracellular domain of the Siglec-F receptor in alveolar 
macrophages. Samples treated with the isotype control had low levels of SHP-1 bands present, 
with all samples having bands around 55kDa and 25kDa, suspected to be the IgG heavy chain 
and IgG light chain respectively.  
 
 
Figure 16: Crosslinking alveolar macrophages using anti-Siglec-F antibodies results in intracellular 
recruitment of SHP-1 to the receptor. Alveolar macrophages isolated from lungs of mice via BAL were crosslinked 
with anti-Siglec-F antibodies, crosslinked with an isotype control antibody or left unstimulated. Siglec-F cell lysets 
were immunoprecipitated and run on an SDS page gel for western blot analysis. Blots were incubated with an anti-
mouse SHP-1 primary antibody and an anti-goat TrueBlot IgG antibody conjugated to HRP. The expected molecular 
weight of SHP-1 is 68kDa. Reactivity of the secondary reagents act as an internal loading control. 
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3.6 Siglec-F crosslinking alone does not activate alveolar macrophages to release TNF-α 
When macrophages are exposed to inflammatory stimuli, in this case LPS, they secrete pro-
inflammatory cytokines such as; TNF-α, IL-1β, IL-6, IL-23 and IL-12. TNF-α (a 185-aminoacid 
glycoprotein) is a cytokine produced during the early acute phase of the inflammatory response 
(Idriss and Naismith, 2000). It is therefore a good readout of macrophage activation due to TLR 
agonists.  
 
Figure 17 shows the concentration of the pro-inflammatory cytokine TNF-α after an 18-hour 
incubation with either crosslinked anti-Siglec-F antibodies, isotype antibodies, LPS (50ng/mL) 
or unstimulated. Siglec-F crosslinking shows no notable increase in the amount of TNF-α 
produced by alveolar macrophages after an 18-hour culture. This data suggests that crosslinking 
Siglec-F does not have a pro-inflammatory effect on alveolar macrophages as far as TNF-α 
production is concerned. 
 
Siglec-F has been proposed to have an inhibitory function due to the presence of ITIMs in its 
cytoplasmic domain. Figure 18 shows that signalling through Siglec-F using crosslinking 
induces a small decrease in TNF-α production when cells are activated with LPS. This reduction 
in TNF-α is consistent with the hypothesis that Siglec-F has an inhibitory function.  
 
 
Figure 17: Alveolar macrophages crosslinked with anti-Siglec-F antibodies do not increase in TNF-α 
production in the absence of stimulation. Alveolar macrophages acquired via BAL were Siglec-F crosslinked for 





Figure 18: Alveolar macrophages crosslinked with anti-Siglec-F antibodies in the presence of LPS results in a 
decrease in TNF-α production. Alveolar macrophages acquired via BAL were crosslinked with anti-Siglec-F or 
isotype control with and without LPS at 50ng/mL for 18 hours, the supernatant was then used to measure TNF-α by 
ELISA. Data representative of one experiment. 
 
3.7 Siglec-F crosslinking induces changes in a panel of different cytokines.  
Following on from the previous preliminary TNF-α experiment, the outcome that receptor 
crosslinking has on the production of several cytokines was further explored. In order to 
accomplish this a LEGENDplex kit was used to simultaneously look at the concentrations of 9 
different pro-inflammatory cytokines. A total of one million macrophages were then stimulated 
with and without LPS in the presence of Siglec-F or isotype control crosslinking.  
The production of G-CSF showed a moderate increase when crosslinked with Siglec-F when 
compared to the isotype control. The expression of chemokines and cytokines like CXCL1, IL-
6, TGF-β1 and TNF-α decreased when Siglec-F is crosslinked on the surface of alveolar 
macrophages under LPS stimulation supporting the hypothesis of this receptor as negative 
regulator. It should be noted that the levels of the cytokine IL-1β increased when macrophages 
were crosslinked with Siglec-F. However, it is interesting that this appears to be independent of 
LPS stimulation. IL-12p70, IL-12p40 and IL-23 were also measured but concentrations were 
undetected by the multiplex bead array assay. 
  





























Figure 19: Crosslinking Siglec-F antibodies results in a change in the production of multiple cytokines. Mouse 
alveolar macrophages acquired via BAL were crosslinked using anti-Siglec-F antibodies or an isotype control in the 
presence (grey bars) and absence of 50ng/mL of LPS (white bars) for 18 hours. Supernatants were collected and 




Table 6: Table reports the mean cytokine concentrations produced by macrophages incubated with/without 
LPS and with/without Siglec-F crosslinking. 
Cytokine Median Cytokine Concentration (pg/mL) 
 
Isotype control + 
LPS Siglec-F + LPS 
Isotype 
control Siglec-F 
CXCL1 950.52 410.87 69.77 63.77 
IL-6 70.91 24.19 2.54 2.82 
GM-CSF 37.02 38.87 37 42.75 
TGF-β1 1087.11 436.24 65.48 57.34 
TNF-α 1976.02 931.32 105.18 126.91 
IL-1β 3.51 9.2 3.76 8.76 
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3.8 Foetal liver cells can adopt macrophage morphology and potentially be used to replace 
primary cells 
The use of animals in science is paramount but the potential induction of pain and stress has 
been of great concern to the general public. That is why in 1959 the principles of humane 
experimental technique (Russell, Burch and Hume, 1959) first proposed the three Rs, standing 
for: Replacement, Reduction and Refinement. It is the concept that as researchers we should 
always be looking for ways to carry out research with a minimal use of animals.  
The average number of alveolar macrophages acquired using BAL is ~150,000 per mouse, 
requiring up to 15 mice for single experiments. In order to replace the need for acquiring 
primary alveolar macrophages, a previously-established protocol was investigated that 
differentiates primary untransformed but self-renewing alveolar macrophage-like cells from the 
foetal livers of mice (FLDAM; Fejer et al., 2013).  
Foetal liver cells obtained from 18-day old C57BL/6 mouse embryos were cultured in 50ng/mL 
of GM-CSF in order to see if the cells would adopt macrophage characteristics after one month 
in culture. After 30 days, cells started to produce clusters similar to those produced by primary 
BMDMs and other macrophages, an identifying characteristic of macrophages. Although cells 
in cultures were morphologically heterogeneous, they were large and showed an elongated 
morphology, a phenotype that is consistent with macrophage characteristics. 
 
 
Figure 20: Mice foetal liver cells incubated with G-CSF for 30 days show macrophages morphology. 
Microscopic pictures of FLDAM incubated with G-CSF at 20x (left) and 40x (right). Pictures shown is a selection of 





3.9 Foetal liver-derived alveolar macrophage-like cells express markers naturally present in 
primary alveolar macrophages  
To further support mouse foetal liver cells adopting an alveolar macrophage-like phenotype 
after incubation with G-CSF, cells were removed from the culture and stained for alveolar 
macrophage markers CD11c, CD200R and Siglec-F. Cell populations were gated according to 
the morphology of macrophages using an FSC vs. SSC dot plot. The expression of these 
markers was then compared to that from alveolar macrophages extracted via BAL. Foetal liver 
cells showed expression of CD11c, CD200R and Siglec-F. Siglec-F expression in alveolar 
macrophages is not shown here, though from literature it has been shown that >89% of alveolar 
macrophages are Siglec-F+ (Svedberg et al., 2019). The expression of Siglec-F was tested in 
alveolar macrophages used in RNA-seq shown in figure 23. 
 
 
Figure 21: Foetal liver cells incubated with G-CSF show similar phenotype to alveolar macrophages. 
Comparative flow cytometry histograms are gated on FSC and SSC and show the expression of the common alveolar 
macrophage markers by FLDAMs after 30 days in the constant presence of 50ng/mL of G-CSF. 21a shows 
representative histograms overlays of lung alveolar macrophages whilst 21b shows cell-surface marker expression of 
FLDAMs. Blue histograms represent unstained background controls and the numbers within each plot show the 






3.10 Foetal liver-derived alveolar macrophage-like cells proliferate in the presence of G-CSF 
media  
If FLDAM are to be considered a possible substitute for primary alveolar macrophages, there 
needs to be a constant supply of cells. To assess whether these cells are able to proliferate in the 
presence of GM-SCF, the expression proliferation marker Ki67 was analysed (Scholzen and 
Gerdes, 2000). After 10 weeks in culture an average 50.8% of FLDAM showed positive levels 
of Ki67 compared to the unstained population suggesting that FLDAM do proliferate when 
cultured with GM-CSF. It is important to mention that cells die in culture in the absence of GM-
SCF (data not shown).  
Though these cells show promise for being a substitute for primary alveolar macrophages the 




Figure 22: FLDAM expresses the proliferation marker Ki67. 22a shows a light microscopy image of FDMs 
clustering (arrows; Scale bar 400µm) when grown in the presence of GM-CSF 50ng/ml for 30 days. 22b shows the 
frequency of Ki67 expressing cells in the culture as a FACS histogram overlay comparing the unstained cells (black) 
and FLDAMs stained with anti-Ki67 antibody (red). The numbers within each plot show the frequency of cells that 
are positive for Ki67. 21c is a bar chart showing cumulative Ki67 expression (MFI ± SD) from three independent 




3.11 RNA sequencing  
3.11.1 The experimental design  
To obtain RNA for sequencing, a crosslinking experiment was designed that would both allow 
for an informational set of samples as well as biological repeats. The sample defined for this 
analysis are shown in table 7. These included a group of samples in culture that were 
crosslinked or left unstimulated and a “reference” sample consisting of RNA from alveolar 
macrophages straight out of the lung.   
 
The composition of the cell suspension obtained by BAL was assessed prior to culturing using 
FACS to assess the proportion of cells that are alveolar macrophages. Figure 23 shows that the 
proportion of cells used in the culture and, therefore, taken for sequencing corresponds to cells 
expressing alveolar macrophage surface markers.   
 
After 18 hours in culture, RNA was extracted and taken for sequencing (see methods). Once the 
sequence data was obtained, statistical analysis were carried out and included: data 
normalisation, graphical exploration of raw and normalised data and testing for differential 
expression for each feature between the conditions. For the purpose of this MRes dissertation a 
preliminary analysis of this data will include: a visualisation of the variability between replicas 
in each condition using PCA and gene ontology analysis of normalised differential expressed 
genes. This will be performed between samples from macrophages that received Siglec-F 
crosslinking or isotype control treatment.     
 
 Table 7: This table shows the conditions and dates of labelled RNA-seq data. 
 
SAMPLE LABEL CONDITIONS DATE 
JST246 Straight out of the lung 24/6/2019 
JST266 Straight out of the lung 26/6/2019 
JSU246 Unstimulated 24/6/2019 
JSU266 Unstimulated 26/6/2019 
JSIC246 Crosslinked with Isotype control 24/6/2019 
JSIC266 Crosslinked with Isotype control 26/6/2019 
JSSF246 Crosslinked with anti-Siglec-F antibodies 24/6/2019 





Figure 23: Cells obtained by BAL are alveolar macrophages with significant purity. FACS plot showing the 
expression of markers characteristic of alveolar macrophages. Numbers in the plots show the frequency of cells 
positive for each cell surface receptor. Data representative of one experiment 
 
3.11.2 Assessment of variability by principal component analysis 
The main source of variability between samples should be due to the differences between 
biological conditions. One way of analysing this is to look at the first principal components of 
the PCA, as shown on the figure 24. On this figure, the first principal component (PC1) is 
expected to separate samples from the different biological conditions, meaning that the 
biological variability is the main source of variance in the data. 
 
The data shows that alveolar macrophages straight out of the lung cluster together tightly, 
suggesting that there is very little variance between these samples. These samples also segregate 
away from cultured samples as expected.  The unstimulated and Siglec-F replicas seem to also 
cluster closely together, this also suggests little variance between data. However, the isotype 
control treated replicas are separated which might limit the differential gene expression analysis. 
This batch variability was taken into consideration in the statistical analysis that underpins the 
gene expression data.  
It is expected that when removed from the lung and placed on plastic in culture for 18 hours 
there will be a variation in gene expression. This is confirmed in figure 25, whereby in all 
volcano plots for JST vs 18 hour alveolar macrophages cultures, many genes experience a large 
fold change. This is demonstrated by the low dashed grey line and large number of red dots.  
Cultures for crosslinked Siglec-F vs crosslinked isotype control show a more defined number of 
genes which have been linked to biological processes. Interestingly there is variation between 








Figure 24: Sample variability expressed as a dot plot of principal components. Data obtained from regularised 
log transformed data. These scatter plots look at the first principal components of PCA. The first graph compares PC1 
(representing the central 85.1% of the data) vs. PC2 (representing 9.36% of the data) and the second figure comparing 
PC1 vs. PC3 (representing 2.58% of the data). Data is shown as coloured dots: Blue; straight out of the lung, Green; 
unstimulated, Red; isotype control and Purple; Siglec-F crosslinked. Numbers are representative of dates 246, 24th of 




Table 8: Number of upregulated, downregulated and total of differentially expressed genes for each 
comparison. 
Test vs Ref Upregulated genes Downregulated genes Total 
Isotype control vs Straight out of the lung  2385 2722 5107 
Siglec-F vs Straight out of the lung 2806 3066 5872 
Unstimulated vs Straight out of the lung 2186 2476 4662 
Siglec-F vs Isotype control 154 142 296 
Unstimulated vs Isotype control 224 285 509 






Figure 25: Volcano blots of comparisons with the red representing significant changes in gene expression. The 
red dots represent genes that have a large fold change when compared with the test (>2) and a high statistical 
significance (-log10 of p value, y axis). The dashed grey line shows where p = 0.05 with points above the line having 
p < 0.05 and points below the line having p > 0.05. The black dots represent genes that have an adjusted P value 
<0.05. 
 
3.11.3 Preliminary gene ontology analysis  
A global gene ontology analysis was carried out, with the aim of exploring the different genes 
that were either differentially upregulated or downregulated by signalling through Siglec-F. To 
recapitulate, these datasets correspond only to the pairwise comparison between cells 
crosslinked with an anti-Siglec-F antibody and its corresponding isotype negative controls 
(JSSF vs JSIC). The complete gene lists can be found in the appendices.  
Figure 26 shows the types of proteins encoded by the genes that were significantly 
downregulated. Among the most frequent were genes that corresponded to enzyme modulators 
with functional relevance to immune cells, such as Lair1 and importantly the kinase activator 
G1-S Cyclin D1. Another important group of genes with immunological function relevant to 
alveolar macrophages include: the chemokine Cx3cl1, the TLR signalling modulator TREM2 
and the IL-6 receptor alpha. It is important to highlight that the data shows that signal 
transduction though Siglec-F modulates its own expression as well as the expression of Siglec-
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E, suggesting a potential regulatory feedback loop and crosstalk between members of the same 
protein family respectively.  
Some pathways can be associated with Siglec-F signalling via the downregulation of gene 
targets. Some of these pathways include: the inflammation mediated by cytokine and 
chemokines, integrin signalling and the gastric-cholecystokinin signalling pathway, the latter 
involved in mucosal biology (see figure 27). 
 It is evident that there might be a potential link between Siglec-F signalling and efferocytosis 
via downregulation of the cell surface receptor tyrosine kinase Axl which is part of the TAM 
family of kinases including TYRO3 and MERTK. 
In contrast, figure 28 shows the types of proteins encoded by genes that were significantly 
upregulated. Among these were important genes that encode nuclear acid binding proteins with 
translation and transcription regulatory activity. Examples of these genes are the translation 
initiation factor Eif4a and Eif4b. Additionally Casp-4, an important gene associated with 
apoptosis, was upregulated upon Siglec-F signalling.     
Finally, figure 29 shows that are several pathways linked with Siglec-F signalling via 
upregulation of gene expression. In this category important pathways such as TGF- β signalling 







Figure 26: Genes that were downregulated upon Siglec-F crosslinking compared to isotype control. This pie 
chart shows the different genes that were downregulated upon Siglec-F crosslinking, whereby area of pie chart 
represents relative amount of downregulation. Genes appear on the pie chart in a clockwise order starting with 




Figure 27: Pathways associated with the genes that were downregulated upon Siglec-F crosslinking compared 
to isotype control. This pie chart shows the different pathways that were downregulated upon Siglec-F crosslinking, 
whereby area of pie chart represents relative amount of downregulation. Pathways appear on the pie chart in a 





   
Figure 28: Genes that were upregulated upon Siglec-F crosslinking compared to isotype control. This pie chart 
shows the different genes that were upregulated upon Siglec-F crosslinking, whereby area of pie chart represents 
relative amount of upregulated. Genes appear on the pie chart in a clockwise order starting with calcium-binding 
protein. Gene lists can be found in appendix one. Graph was created using PANTHER. 
 
   
Figure 29: Pathways associated with genes that were upregulated upon Siglec-F crosslinking compared to 
isotype control. This pie chart shows the different pathways that were upregulated upon Siglec-F crosslinking, 
whereby area of pie chart represents relative amount of upregulation. Pathways appear on the pie chart in a clockwise 






4.1 The rationale for characterising the outcomes of Siglec-F signalling 
The overall aim of the project was to design a system that could induce specific signals through 
Siglec-F and explore the outcomes which, to date, are very poorly understood. Siglec-F has 
been proven to be expressed in high amounts on alveolar macrophages, eosinophils and some 
activated T cells (Zhang et al., 2007) being attributed as a modulator of apoptosis in eosinophils 
(O’Reilly and Paulson, 2009). Preliminary analysis of alveolar macrophage function have failed 
to address the role of this molecule in regulating phagocytosis and to date no data has been 
produced to support its role in the regulation of cytokine production (Feng and Mao, 2012).   
The lung microenvironment is rich in molecules that contain the natural ligands for Siglec-F and 
studies have shown that there is a regulatory interaction between mucins containing sialic acids 
and alveolar macrophage activity (rev in Janssen et al., 2016). 
The data generated in this study, although preliminary, could provide further evidence to 
support the role of this molecule as a regulator of alveolar macrophage activity. 
 
4.2 Siglec-F is highly expressed on alveolar macrophages 
When comparing macrophages obtained via BAL with macrophages obtained from the 
peritoneal cavity and in-vitro-differentiated macrophages; the majority of alveolar macrophages 
expressed the Siglec-F receptor. Existing literature shows that Siglec-F is expressed on upwards 
of 90% of cells extracted via BAL (Svedberg et al., 2019), whereas in the current data only 70-
80% of cells are expressing Siglec-F (shown in figure 8). This lower percentage yield is likely 
due to a small blood contamination likely caused by cervical dislocation. This contamination 
results in a myeloid population which have similar FSC vs. SSC properties to macrophages as 
well as also expressing F4/80. To control and minimise the consequences of having this 
confounder, mice used for RNA-seq analysis were sacrificed using lethal injection with 
pentobarbital (100mg/Kg; at UCL). To check for contaminations of samples used for RNA-seq, 
FACS staining was used for several alveolar macrophage-specific cell surface receptors to 
identify and gate on these cells. This is demonstrated in figure 23 where markers CD11c, 
MERTK and Siglec-F were used to identify alveolar macrophages for RNA-seq analysis. These 
markers can also be used to distinguish between alveolar macrophages, interstitial macrophages 
and monocytes if there was a contamination (Svedberg et al., 2019). 
As shown in figure 8, the high level of expression of Siglec-F seen in alveolar macrophages 
contrast with the low levels seen in lung interstitial macrophages. This result suggests that the 
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presence of the receptor is not expressed in all tissue resident macrophages, with Siglec-F also 
being absent in conventional dendritic cells and monocytes when at a steady state (Misharin et 
al., 2013; Sabatel et al., 2017; Gibbings et al., 2017). This data combined alveolar macrophage 
ontology and cell fate studies, which support the idea that interstitial macrophages originate 
from circulating monocytes and may be an intermediate stage in the development and migration 
to the airways (Landsman and Jung, 2007), and in this process, they acquire a robust expression 
of Siglec-F. 
4.3 Are alveolar macrophages M1 or M2 
The results show that most of the Siglec-F expressing alveolar macrophages exist as classically 
activated macrophages (Figures 11 and 12: 92.1%), this supports the highly inflammatory 
nature of alveolar macrophages. Though it is important to mention that 2.51% of alveolar 
macrophages are both CD38+ and Arg1+. This observation has been previously reported as 
alveolar macrophages can exhibit characteristics of both pro-inflammatory and tolerogenic 
macrophages (Quillay et al., 2014). However this data suggests that most macrophages exist as 
M1 macrophages, this is in contrast to previous research that states the majority of the alveolar 
macrophage population exist as a duo phenotype (Mitsi et al., 2018).  Nevertheless, this data 
provides evidence that not all alveolar macrophages, and possibly not all tissue macrophages, 
fall into the M1/M2 classification and perhaps have a more diverse plasticity (See Figure 10). It 
is possible that this duo phenotype is essential in maintaining a balance between immune 
response against pathogens and immune tolerance (Mitsi et al., 2018). 
Figure 13 shows that both CD38+ and CD38+Arg1+ cells express Siglec-F (>80%), this is to be 
expected as in figure 8, 72% of alveolar macrophages obtained via BAL express Siglec-F. The 
expression of Siglec-F in CD38+ and CD38+Arg1+ cells are comparable and thus Siglec-F 
cannot be used as a distinguishing feature for M1 or M2 alveolar macrophages.   
Alveolar macrophages are heterogeneous with a small proportion of them expressing distinct 
phenotypic markers which could be due to macrophage plasticity (Hussell and Bell, 2014). 
Expression of these receptors might change under specific situations; like allergen exposure 
inducing Arg1 or bacterial or viral infections which would induce expression of CD38 (Gordon, 
Plüddemann and Martinez Estrada, 2014). 
 
4.4 Siglec-F can be successfully targeted 
The Siglec-F antibody crosslinking system was shown to successfully target the Siglec-F 
receptor demonstrated in figure 14. This figure shows a decrease in florescence after antibody 
crosslinking of the Siglec-F receptor. It is important to state that this decrease is not 100%, this 
is important as it is unlikely that in vivo mucin5b or other ligands will bind to all the Siglec-F 
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receptors on an alveolar macrophage. The levels of receptor targeting in these experiments were 
kept constant by keeping the same concentration of crosslinking reagents across all experiments. 
However, the physiological level of signal strength provided by crosslinking cannot be easily 
compared with that of the natural ligands. 
Data from the western blot experiment (Figure 16) showed that Siglec-F can be signalled using 
antibody crosslinking, by assessing that SHP-1 was recruited to the Siglec-F receptor. 
Interestingly SHP-1 was also recruited to a receptor in the case of the isotype control. This 
behaviour can be hypothesised to have occurred as the FC region located on all antibodies could 
have bound to a FC receptor on the alveolar macrophages, leading to SHP-1 recruitment to the 
ITAM located in the cytoplasmic tail (Abram and Lowell, 2017). To further explore this 
hypothesis this experiment would need to be repeated using CD16/32 or another FC blocker.  
It is important to note that the presence of SHP-1 on the western blot is not definitely caused by 
the protein being bound to the intracellular domain of the Siglec-F receptor. This is due to the 
methodology as the blot was never stripped and incubated with fluorescently conjugated Siglec-
F antibodies.  Further work could therefore develop on this method and strip the blot after the 
incubation and reading of SHP-1 as well as repeating the incubation with primary anti-Siglec-F 
antibodies. Confirmation of the presence of both the Siglec-F receptor and SHP-1 would 
strengthen this claim.  
 
4.5 Do alveolar macrophage undergo apoptosis upon Siglec-F crosslinking? 
A well-documented effector function of Siglec-F crosslinking in eosinophils is that they 
undergo apoptosis (Zhang et al., 2007). However, it is unknown whether crosslinking Siglec-F 
on the surface of alveolar macrophages stimulates apoptosis. To test whether this occurs in 
alveolar macrophages populations were incubated with: crosslinked anti-Siglec-F antibodies, an 
isotype control, left unstimulated or incubated with known immune stimulant LPS. The levels of 
apoptotic cell marker, phosphatidylserine, was then measured at different time points by binding 
annexin V.  
Data showed that antibody crosslinking of the Siglec-F receptor on alveolar macrophages does 
not induce apoptosis like in eosinophils as shown in figure 15. In this figure, the expression of 
phosphatidylserine in alveolar macrophages where Siglec-F receptors were crosslinked were 
comparable to that of the unstimulated population. Siglec-F crosslinking also induces similar 
levels of apoptosis to that seen in macrophages incubated with the isotype control, meaning that 
the use of antibodies does not cause apoptosis. Cell death does occur minimally at 18 hours, but 
cell death is greater at 24 hours, this is likely due to extended absence from the lung 
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environment. It is for this reason 18 hours was chosen as a suitable time point for RNA 
sequencing. 
 
4.6 Proinflammatory cytokine production is reduced by Siglec-F crosslinking 
From the apoptosis data it was concluded that alveolar macrophages do not apoptose after 
Siglec-F crosslinking and natural cell death is minimal at 18 hours. It is for this reason that 
alveolar macrophages were incubated for 18 hours for the cytokine experiments. 
Cytokine production was used to measure the immune activity of alveolar macrophages as 
alongside chemokines their production are some of the initial effector functions of an activated 
macrophage (Arango Duque and Descoteaux, 2014). Initially the production of TNF-α was 
considered, a cytokine produced in the acute phase of inflammation (Idriss and Naismith, 2000) 
and will thus be at relatively high concentrations after 18 hours of stimulation with and without 
LPS. The data shows a relatively large concentration of TNF-α when incubated with LPS, as to 
be expected as LPS is a strong stimulator of macrophage immune response (Han et al., 2017). 
When Siglec-F is crosslinked, the concentrations of TNF-α are similar to that of the 
unstimulated macrophage population. This suggests that crosslinking Siglec-F does not result in 
a proinflammatory effector function. Concentrations of TNF-α were comparable when 
crosslinked with anti-Siglec-F antibodies or with isotype control suggesting that using 
antibodies has little or no effect on production of this cytokine. When alveolar macrophages are 
crosslinked with Siglec-F in the presence of LPS there is a decrease in the amount of TNF-α 
produced when compared to that of just LPS. This means that crosslinking Siglec-F results in 
negative regulation of the production of proinflammatory cytokine TNF-α. To further support 
this theory a multiplex cytokine bead array was performed that looked at nine different 
cytokines; G-CSF, CXCL1, IL-1β, IL-23, IL-12p70, IL-12p40, IL-6, TNF-α, and TGF-β1. In all 
repeats of this experiment IL-12p70, IL-12p40 and IL-23 concentrations were undetected by the 
multiplex kit. Lack of IL-12p70 production has been observed in alveolar macrophage 
activation by LPS (Isler et al., 1999), however the same paper observed an increase in the 
production of cytokine IL-12p40 (Isler et al., 1999). IL-12p70 has been shown to be produced 
by alveolar macrophages when activated by LPS alongside an IL-10 production inhibitor (Isler 
et al., 1999). In an in vitro environment LPS binds to TLR4, inhibiting IL-10 production though 
this is alongside TLRs 2 and 9 (Fernandez et al., 2004). IL-23 production has been seen to be 
induced by LPS (Bosmann et al., 2013). However, in this instance mice inhaled LPS, inducing 
lung inflammation in vitro (Bosmann et al., 2013).  
  
CXCL1 is a chemokine playing a pivotal role in recruiting and activating neutrophils (Altmann 
et al., 2012), and thus is produced in relatively small amounts by resting macrophages as seen in 
figure 19. When activated the alveolar macrophages begin to produce an increased amount of 
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the chemokine (Altmann et al., 2012), with reductions in CXCL1 production being used to 
measure decreases in lung inflammation (Altmann et al., 2012). Increases in CXCL1 are also 
seen in acute lung injury (Altmann et al., 2012). The crosslinking of Siglec-F reduces the 
production of CXCL1 (shown in figure 19) indicating inhibition of the CXCL1 production 
pathway. 
 
TGF-β is generally considered a central mediator of the resolution phase of tissue injury, 
inhibiting tissue inflammation and enhancing scarring (Khalil et al., 1989), with signalling of 
the TGF-β receptor being required for the homeostasis of alveolar macrophages (Yu et al., 
2017). These results showed an increase in concentration of the cytokine when alveolar 
macrophages were activated with LPS. This suggests an important role in the initial stages of 
development, where the cytokine acts as a potent chemoattractant for monocytes, lymphocytes, 
neutrophils and fibroblasts (Breit and Wahl, 2001). This imbalance between the immune 
resolution and proinflammatory activities of TGF-β can cause chronic states of inflammation 
(Breit and Wahl, 2001). In figure 19 there is a percentage decrease of 60% in concentration 
when crosslinked with Siglec-F in the presence of LPS, suggesting an anti-inflammatory role 
for the receptor during the innate stages of inflammation. Decreases in TGF-β expressing cells 
after crosslinked Siglec-F has been seen in previous research (Song et al., 2009). However, this 
finding was observed using eosinophils and as discussed previously, there are differences in 
functional outcomes as a result of Siglec-F signalling in macrophages vs eosinophils 
(apoptosis). Therefore, more research into Siglec-F crosslinking effecting TGF-β production by 
alveolar macrophages is needed to strengthen existing literature. 
 
IL-6 has been previously shown to enhance the polarisation of alternatively activated 
macrophages (Fernando et al., 2014) in synergy with cytokines IL-4 and IL-13, with more 
recent research suggesting IL-6 might also play an essential role in the Th2-mediated allergic 
response (Deo et al., 2010). The role of this cytokine for polarisation of alternatively activated 
macrophages may explain the cytokines lower concentrations when compared to that of TNF-α, 
CXCL1 and TGF-β1, as alternatively activated macrophages represent a small percentage of the 
population (seen in figure 11). Alveolar macrophages have been shown to contribute the largest 
fraction of IL-6 in the lungs (Gubernatorova et al., 2018) with elevated levels of the cytokine 
being a major contributor to the pathogenesis of asthma (Gubernatorova et al., 2018). The 
reduction in the presence of Siglec-F crosslinked suggests an anti-inflammatory role and shows 
opportunity for Siglec-F being a possible treatment for asthma. 
  
When looking at results for LEGENDplex there are two graphs that are different from all others, 
the first being IL-1β, a cytokine that is involved in pain, inflammation and autoimmune 
conditions. The results for this cytokine are an increased concentration when crosslinked with 
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Siglec-F independent of LPS. Currently it is unknown why this occurs though due to the 
relatively low concentrations this could have occurred due to chance. The lack of CXCL1 
production could be due to the absence of neutrophils in the culture. Neutrophils are thought to 
be the sole source of the cytokine though neutrophils have been suggested to indirectly mediate 
IL-1β release in macrophages (Peiró et al., 2017). Levels of G-CSF seem to be consistent across 
all samples regardless of crosslinking and LPS, this can be explained as G-CSF is a colony 
stimulating factor that stimulates cells to proliferate which within an alveolar macrophage 
population is essential as these cells possess the ability of self-renew without a contribution 
from the bone marrow (Hashimoto et al., 2013). The relatively low though similar 
concentrations highlight this fact as alveolar macrophages need to maintain a consistent 
population to prevent over colonisation. This is in contrast with published literature that 
concluded alveolar macrophages produced large amounts of G-CSF following endotoxin 
exposure (Tazi et al., 1991), though this was in the case of exposure to bacterial pneumonia and 
sarcoidosis. 
 
It was concluded that alveolar macrophages are active after 18 hours and alongside the 
apoptosis data, 18 hours of incubation was chosen for the RNA-seq experiments.  
 
4.7 FLDAM, a viable alternative to primary alveolar macrophages 
Alveolar macrophages are cells crucial to the immune response in the lung (Davies et al., 2013). 
Though due to the low yield acquired from the lungs of mice coupled with the plasticity of 
macrophages, the study of their distinct effector functions is somewhat hampered. The 
establishment of an in vivo self-replicating culture of alveolar macrophage-like cells is therefore 
essential in the further study of alveolar macrophages both for potential cost savings and to be 
in line with the 3Rs (Russell, Burch and Hume, 1959).  
 
After a 30-day incubation with GM-CSF the mice liver foetal cells display traits associated with 
macrophages. Flow cytometry analysis (figure 21) showed that these cells are heterogenous and 
seem to resemble primary alveolar macrophages and therefore could be used as an alternative. 
Though the percentage of foetal liver cells expressing the Siglec-F receptor (29.7%) is far fewer 
compared to the high 90% expression of Siglec-F seen by other researchers (Svedberg et al., 
2019). Previous work on foetal liver cells cultured with GM-CSF observed the presence of 
alveolar macrophage receptors MARCO, Chl3l and CD11c (Fejer et al., 2013) with the latter 
also being observed in this data (59.1%). To further support the claim of being alveolar 
macrophage like cells more functional and activation analysis is needed.  
 
An important trait to consider when finding a suitable alternative for alveolar macrophages is 
the ability of the FLDAM to self-replicate. When in the presence of the GM-CSF these cells can 
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be seen to replicate demonstrated by the presence of Ki67, a marker of cell proliferation. Foetal 
liver cell cultures can repopulate after populations are removed and used in experiments, as long 
as initial population is >1x106 cells, and seem to grow exponentially (Fejer et al., 2013). With 
this evidence for self-renewal, it could be possible to calculate the rate at which FLDAM 
replicate, thus being able to take populations for use more regularly once a population has 
reached an estimated number.  
 
4.8 Crosslinking Siglec-F results in downregulation of immune related pathways  
RNA-seq is a widely used practice that allows researchers to profile gene expression (Chu and 
Corey, 2012; Wang, Gerstein and Snyder, 2009), with this information then being able to be 
linked with pathways. The data showed that a total of 296 genes were either up or 
downregulated as a result of Siglec-F crosslinking with key genes such as TREM2 and Axl being 
downregulated. Axl is an important mediator of efferocytosis (Grabiec et al., 2018), suggesting 
that downregulation of this receptor would reduce the efferocytotic capacity of alveolar 
macrophages when Siglec-F is crosslinked, with the alveolar macrophages that are deficient in 
Axl displaying reduced efferocytotic capacity (Grabiec et al., 2018). A reduction in Axl mRNA 
is also seen in patients with moderate-to-severe asthma, a disease where efferocytosis is 
impaired (Grabiec et al., 2017). 
 
The downregulation of TLR signalling modulator TREM2 could suggest a regulatory function 
as TREM2 expression on macrophages promotes phagocytosis of apoptotic neurons and 
bacteria (Humphrey, Xing and Titus, 2015). TREM2 does this with minimal proinflammatory 
cytokine production (Humphrey, Xing and Titus, 2015). The receptor is also seen to be 
upregulated during induced pulmonary inflammation (Turnbull et al., 2006). Interestingly the 
downregulation of TREM2 has been seen to increase the production of TNF-α and IL-6 in 
response to LPS in BMDM and peritoneal macrophages (Turnbull et al., 2006). More research 
is needed to see if this occurs with alveolar macrophages. 
 
TLR8 is an endosomal receptor found inside macrophages (Guiducci et al., 2013) and is 
primarily responsible for recognising single-stranded RNA (Eng, Hsu and Lin, 2018). When 
activated TLR8 has been linked to an increase in the mRNA levels of TNF-α and IL-6 (Eng, 
Hsu and Lin, 2018), this is mirrored whereby both cytokines were reduced when Siglec-F was 
crosslinked in the presence of LPS (figure 19). 
 
4.9 Concluding remarks 
This project uncovered significant data of how crosslinking Siglec-F in alveolar macrophages 





4.10 Future research 
The research performed in this dissertation has looked at the effect of signalling alveolar 
macrophages through the cell surface receptor Siglec-F, the results of which would benefit from 
further research. 
 
RNA-sequencing of Siglec-F crosslinked alveolar macrophages showed a decrease in Axl, a 
marker associated with efferocytosis. To establish cause and effect, future research should 
consider performing an efferocytosis assay after alveolar macrophages are crosslinked with 
Siglec-F for 18 hours. 
 
Research into FLDAM being a possible substitute for primary alveolar macrophages looks 
promising however as discussed earlier more work needs to be done solidifying this claim. 
Similar to how production of cytokines was measured in this discussion, a multiplex kit can be 
used to measure the concentration of cytokines in the presence of LPS and/or crosslinked 
Siglec-F antibodies. The comparison of this data with that obtained in this dissertation could 
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6. Appendix 1 
List of differentially up-regulated genes resulting from a pairwise comparison between cells 
crosslinked with an anti-Siglec-F antibody and its corresponding isotype negative control (JSSF vs 
JSIC). The list reports normalised counts, fold change, Log2Fold change, p and adjusted p values for 
samples labelled as 246 and 266 each corresponding to one independent biological replica. 
  
Id norm.JSIC246 norm.JSIC266 norm.JSSF246 norm.JSSF266 FoldChange log2FoldChangepvalue padj
Ddit3 509 492 1513 1456 2.965 1.568 1.10E-29 1.17E-25
Aars 4715 3959 8527 8213 1.934 0.952 4.50E-21 2.40E-17
Mthfd2 1953 1563 4051 4420 2.422 1.276 1.14E-19 4.04E-16
Asns 1272 955 3202 3483 3.068 1.617 1.45E-17 3.87E-14
Cyb5r1 935 893 1948 1814 2.056 1.04 8.16E-17 1.74E-13
Gbp8 161 221 476 644 2.934 1.553 9.62E-16 1.71E-12
Hspa9 7188 6581 12390 13243 1.867 0.901 1.64E-15 2.49E-12
Trib3 425 335 1497 1464 3.969 1.989 4.81E-15 6.41E-12
Slc7a5 966 712 1830 1877 2.222 1.152 2.36E-14 2.80E-11
Ccdc47 1486 1390 2445 2578 1.747 0.805 1.03E-13 1.01E-10
Eprs 4889 4257 7737 7837 1.709 0.773 1.04E-13 1.01E-10
Slc43a3 185 178 492 531 2.807 1.489 1.35E-13 1.20E-10
Atf5 999 726 1866 1467 1.939 0.955 1.53E-13 1.25E-10
Sars 2795 2624 4523 4313 1.631 0.705 3.87E-13 2.94E-10
Psat1 701 618 1358 1203 1.945 0.959 4.34E-13 3.08E-10
Phgdh 617 662 1375 1387 2.161 1.112 1.02E-12 6.79E-10
Pck2 820 733 1531 1702 2.078 1.055 1.52E-12 9.51E-10
Slc7a1 1544 1220 3151 3552 2.46 1.299 8.45E-12 4.74E-09
Atf4 4800 4063 8618 8371 1.928 0.947 1.25E-11 6.66E-09
Aqp9 190 141 478 498 2.984 1.577 2.42E-11 1.22E-08
Nfe2l1 6081 5633 8875 9796 1.594 0.672 2.51E-11 1.22E-08
Ghitm 4411 4246 6850 8433 1.763 0.818 3.52E-11 1.63E-08
Yars 1001 930 1659 1710 1.744 0.802 4.51E-11 1.92E-08
Gtpbp2 1892 1554 3446 3650 2.053 1.038 6.06E-11 2.49E-08
Xpot 1704 1611 2678 2876 1.678 0.747 1.44E-10 5.48E-08
Arsg 848 821 1525 1471 1.794 0.843 1.71E-10 6.29E-08
Nars 4041 3792 5911 5794 1.495 0.58 1.91E-10 6.78E-08
Slc38a2 2837 2460 4214 4576 1.66 0.731 3.74E-10 1.25E-07
Rhbdd1 1134 961 1789 1757 1.696 0.762 4.74E-10 1.49E-07
Eif3c 6684 6272 9554 9781 1.494 0.579 7.98E-10 2.43E-07
Aldh18a1 813 738 1383 1398 1.789 0.839 1.24E-09 3.56E-07
Shmt2 705 652 1209 1251 1.812 0.857 1.08E-08 2.88E-06
Dusp1 438 390 659 850 1.825 0.868 1.36E-08 3.54E-06
Sesn2 756 601 1342 1278 1.938 0.954 1.45E-08 3.67E-06
Cask 716 659 1144 1151 1.672 0.742 2.91E-08 7.20E-06
Cars 1372 1055 2131 2123 1.759 0.815 3.34E-08 8.10E-06
Ppp1r15a 675 536 1234 1339 2.159 1.11 4.88E-08 1.15E-05
Rgl1 3670 3484 5102 6332 1.596 0.674 7.70E-08 1.75E-05
Hid1 100 60 254 198 2.897 1.534 9.19E-08 2.00E-05
Mars 1663 1484 2441 2476 1.561 0.642 1.25E-07 2.66E-05
Ifrd1 1537 1358 2390 3120 1.92 0.941 1.63E-07 3.34E-05
Taf15 1192 1056 1775 1857 1.611 0.688 1.75E-07 3.52E-05
Scpep1 4564 3863 6211 6119 1.467 0.553 2.04E-07 3.95E-05
Sqstm1 15689 13483 24103 23564 1.643 0.717 2.55E-07 4.86E-05
Soat2 84 56 257 223 3.454 1.788 2.98E-07 5.48E-05
Ahcyl1 4889 4474 6591 7990 1.557 0.639 3.25E-07 5.88E-05
Ptgir 3760 3079 5829 5501 1.668 0.739 4.20E-07 7.11E-05
Ero1l 1159 1037 1661 1781 1.573 0.653 7.54E-07 0.00012565
Pim1 1031 850 1395 1567 1.578 0.658 1.59E-06 0.00025269
Iars 1997 1862 2796 2931 1.484 0.569 1.72E-06 0.00026531
Ago2 3556 3262 4922 5301 1.503 0.588 1.75E-06 0.00026683
Gpr141 363 479 559 844 1.65 0.722 1.83E-06 0.00027508
Slc39a2 1523 1173 2060 1886 1.475 0.561 1.94E-06 0.00028685
Maoa 3967 3338 5180 5824 1.512 0.597 2.34E-06 0.00034089
Mtmr3 2754 2641 3649 3749 1.371 0.455 2.37E-06 0.00034089
Hspa1b 58 57 142 183 2.872 1.522 3.06E-06 0.00042397
Ern1 989 865 1526 1468 1.613 0.689 3.59E-06 0.00048416
Rabggtb 525 540 811 864 1.573 0.653 3.54E-06 0.00048416
Dgkg 381 386 755 592 1.752 0.809 3.72E-06 0.00048903
Eif2s2 1211 1149 1786 2142 1.67 0.74 4.05E-06 0.00052605
Cox6a2 31 18 114 138 5.045 2.335 4.36E-06 0.00055673
Gyg 2042 2262 2749 3121 1.364 0.447 5.27E-06 0.00066144
Chac1 143 95 329 349 2.958 1.564 6.61E-06 0.00081975
Mt2 4458 3051 5791 5754 1.573 0.653 6.71E-06 0.00082256
Lonp1 1337 1294 1891 1849 1.421 0.507 8.00E-06 0.00093771
Rora 1053 998 1423 1724 1.533 0.616 9.38E-06 0.00107541
Pfkp 1819 1663 2394 2309 1.352 0.435 9.50E-06 0.00107763
Zbtb18 539 459 793 778 1.581 0.661 9.80E-06 0.00108863
Nfil3 233 193 379 302 1.598 0.676 1.04E-05 0.00114311
Tbpl1 327 343 534 594 1.688 0.755 1.09E-05 0.00118514
Eif4ebp1 511 482 817 762 1.588 0.667 1.29E-05 0.00137874
Ch25h 714 921 993 1521 1.517 0.602 1.33E-05 0.00140107
Cdkn1a 1874 1334 2719 2268 1.575 0.655 1.45E-05 0.00151175
Pogk 1543 1151 2035 2216 1.599 0.677 1.47E-05 0.00151175
Tbc1d31 449 457 709 781 1.642 0.716 1.46E-05 0.00151175
Atp11a 1686 1479 2313 2053 1.38 0.465 1.50E-05 0.00151508
Npc1 11869 11079 14761 15341 1.312 0.392 1.51E-05 0.00151508
2410006H16Rik 69 103 178 216 2.319 1.214 1.73E-05 0.00171193
Trim35 1490 1339 1958 2017 1.407 0.493 2.40E-05 0.00226647
Slamf7 1212 995 1697 2362 1.862 0.896 2.47E-05 0.0023063
Arhgef3 1264 1265 1759 2154 1.533 0.617 3.41E-05 0.00293383
Fyn 692 644 975 1060 1.526 0.61 4.89E-05 0.00395164
Gadd45a 352 285 692 782 2.361 1.24 5.01E-05 0.00398211
Sorbs3 2175 2019 3033 3080 1.454 0.54 5.19E-05 0.00410096
Glrp1 46 49 133 142 2.904 1.538 5.88E-05 0.00457701
Lrp12 6537 6075 8013 8926 1.344 0.426 6.35E-05 0.00483751
Mreg 1138 1091 1696 1859 1.599 0.677 7.65E-05 0.00554989
Sp140 427 473 642 700 1.491 0.577 7.57E-05 0.00554989
Glce 450 445 697 663 1.519 0.603 8.14E-05 0.00582624
Hspa1a 57 44 143 114 2.553 1.352 8.28E-05 0.00588683
Ly9 6446 5751 7944 8259 1.332 0.414 8.35E-05 0.00589861
Slc6a9 256 140 416 376 2.106 1.074 8.57E-05 0.00597242
Lars 1778 1649 2314 2377 1.368 0.452 9.32E-05 0.00637251
Tars 1279 1230 1676 1756 1.367 0.451 9.28E-05 0.00637251
Zc3hav1 1905 1873 2649 2974 1.491 0.576 9.91E-05 0.00672635
Wars 1265 1243 1773 1608 1.347 0.43 0.00011737 0.00782055
Ccbe1 1193 984 1531 1767 1.51 0.595 0.00012029 0.00794028
Zyg11b 1352 1375 1734 2331 1.484 0.569 0.00015046 0.00943591
Rassf8 488 300 738 570 1.699 0.765 0.00015629 0.00974365
Inhba 187 141 383 475 2.766 1.468 0.00020127 0.01198707
Gpt2 447 381 662 718 1.672 0.742 0.00020735 0.01214608
Tmbim1 5059 4358 6479 5673 1.291 0.368 0.00020547 0.01214608
Eif4b 6379 6612 7775 8354 1.241 0.312 0.00022888 0.01311897
Phf10 695 637 955 929 1.414 0.5 0.00023148 0.01319704
Lrrfip2 1819 1610 2295 2376 1.366 0.45 0.00024086 0.01358652
Arpc5l 622 575 830 862 1.415 0.5 0.00025825 0.01411914
Galnt6 4511 4020 5486 5197 1.254 0.326 0.0002651 0.01421725
Mlx 858 811 1153 1147 1.377 0.462 0.00026538 0.01421725
Rbbp8 665 655 950 1135 1.583 0.662 0.0002766 0.01459797
Osbpl9 3567 3416 4371 4745 1.305 0.384 0.00029081 0.01519755
Ctage5 2629 2855 3423 3731 1.305 0.384 0.00029461 0.01532129
Casp4 259 267 399 444 1.608 0.685 0.0003008 0.01545787
Rpl23 5321 5704 6949 7242 1.288 0.365 0.00030119 0.01545787
Setd8 6319 5906 7720 8179 1.302 0.381 0.00031312 0.01596601
Zfand3 2050 1782 2450 2755 1.36 0.444 0.0003145 0.01596601
Vegfa 140 102 239 246 2.072 1.051 0.00035283 0.01765984
Usp1 728 795 1003 1052 1.35 0.433 0.00037514 0.01860177
Nup62 1049 892 1415 1382 1.439 0.525 0.00037832 0.01862811
Mdfic 1395 1227 1690 1971 1.398 0.484 0.00039858 0.01931458
Gars 4895 4744 6274 6033 1.276 0.352 0.00040826 0.01960577
H2-Q4 684 554 886 827 1.39 0.475 0.00042139 0.01996626
Ppapdc1b 320 322 475 489 1.503 0.588 0.00043555 0.02054623
Ubr2 2740 2528 3590 3617 1.366 0.45 0.00044121 0.02072128
Plekhg1 7262 6963 8569 9974 1.3 0.379 0.00046688 0.02173536
Jdp2 206 204 322 357 1.66 0.732 0.00050178 0.0230882
Napepld 442 388 602 644 1.499 0.584 0.00050061 0.0230882
Eif5 3776 3532 4609 6240 1.484 0.57 0.00052428 0.02364686
Il7r 1115 639 1433 1471 1.77 0.824 0.00051981 0.02364686
Slc3a2 10586 8669 14598 14874 1.55 0.632 0.00052272 0.02364686
Ctsl 9389 8612 12454 11375 1.324 0.405 0.00057686 0.02562462
Ubap1 2161 2111 2765 2870 1.319 0.4 0.00060932 0.02651421
Epb4.1 1679 1568 2031 2153 1.29 0.368 0.00062599 0.02710958
Ticam2 1272 1390 1823 2037 1.448 0.534 0.00066248 0.02813817
Pik3ap1 6578 6796 8023 8228 1.215 0.281 0.00074367 0.03109137
Cd83 569 386 735 625 1.45 0.536 0.00076062 0.03143019
Map1b 213 125 325 257 1.764 0.819 0.0008501 0.03459141
Ppp1r15b 3722 3811 4590 4848 1.253 0.325 0.00088049 0.03542221
Tspan5 1198 1206 1501 1618 1.297 0.375 0.00087791 0.03542221
Atp6v1c1 9231 8624 10993 11298 1.25 0.321 0.00090645 0.03619349
Zdhhc18 1871 1436 2223 2476 1.431 0.517 0.00092307 0.03658328
Arl14ep 506 446 666 700 1.435 0.521 0.00093796 0.03703562
Mtbp 126 110 237 198 1.84 0.88 0.00107144 0.04184099
Optn 1543 1512 1981 2262 1.391 0.476 0.00110315 0.04276602
Sun2 3515 3163 4153 4108 1.238 0.308 0.00112419 0.04342382
Metrnl 1359 1537 1927 1853 1.309 0.388 0.00119874 0.04580571
Stxbp5 982 744 1227 1092 1.355 0.438 0.00124465 0.04705402
Mib2 945 798 1275 1253 1.446 0.533 0.00124971 0.0470783
Evi5 795 780 1058 1118 1.381 0.466 0.00125666 0.04717358
Cdk5rap2 1073 953 1342 1333 1.32 0.4 0.00129641 0.04755749
Ffar2 27 32 81 56 2.303 1.203 0.00129221 0.04755749
Lcp2 2779 2815 3329 3707 1.258 0.331 0.00128038 0.04755749
Esyt2 4908 4175 5641 6026 1.288 0.365 0.00130678 0.0476904
Osgin2 213 181 338 393 1.889 0.918 0.00137089 0.0495447
Papd5 1885 1770 2274 2343 1.262 0.336 0.00138408 0.04985017
6. Appendix 2 
List of differentially down-regulated genes resulting from a pairwise comparison between cells 
crosslinked with an anti-Siglec-F antibody and its corresponding isotype negative control (JSSF vs 
JSIC). The list reports normalised counts, fold change, Log2Fold change, p and adjusted p values for 
samples labelled as 246 and 266 each corresponding to one independent biological replica. 
 
Id norm.JSIC246 norm.JSIC266 norm.JSSF246 norm.JSSF266 FoldChange log2FoldChange pvalue padj
Dhcr24 1514 1794 871 871 0.528 -0.922 2.12E-12 1.25E-09
Kctd12 2840 4002 1806 1929 0.551 -0.86 4.45E-11 1.92E-08
Tlr8 2710 3046 1524 1978 0.606 -0.722 8.36E-11 3.30E-08
Ear1 991 1356 648 637 0.552 -0.858 3.58E-10 1.23E-07
Cd180 1133 1405 673 721 0.551 -0.86 4.06E-10 1.31E-07
Alox5 1316 1662 867 764 0.551 -0.86 1.15E-09 3.39E-07
Scd2 3206 3845 1762 2021 0.537 -0.897 3.60E-09 1.01E-06
Kazald1 306 457 175 149 0.431 -1.216 6.16E-09 1.68E-06
Emb 1326 1431 914 719 0.588 -0.765 5.10E-08 1.18E-05
Fasn 3423 3671 2413 2248 0.658 -0.604 8.74E-08 1.94E-05
Sdf2l1 1581 2061 1101 1147 0.62 -0.689 1.51E-07 3.16E-05
P2ry6 704 863 446 404 0.545 -0.875 1.83E-07 3.61E-05
Gusb 6708 7408 5117 4647 0.692 -0.532 2.96E-07 5.48E-05
Siglecf 2108 2739 1501 1018 0.52 -0.944 3.59E-07 6.37E-05
Emilin1 1385 1546 901 962 0.636 -0.653 3.79E-07 6.52E-05
Pros1 924 1268 664 698 0.626 -0.675 3.74E-07 6.52E-05
5031439G07Rik 4449 5071 3396 3415 0.716 -0.481 1.05E-06 0.00017219
Pald1 1127 1376 794 555 0.539 -0.892 1.14E-06 0.00018449
Cyth4 5977 6560 4546 3813 0.667 -0.585 1.72E-06 0.00026531
Crip1 933 769 653 450 0.64 -0.643 2.74E-06 0.00038883
Fscn1 671 340 411 190 0.588 -0.767 3.00E-06 0.00042039
Tuba4a 1822 1731 1374 1104 0.694 -0.527 3.64E-06 0.00048565
Rgs2 1289 1764 945 842 0.585 -0.773 4.39E-06 0.00055673
Myh14 282 162 161 78 0.528 -0.922 6.93E-06 0.0008398
Cx3cl1 625 693 449 319 0.579 -0.788 8.00E-06 0.00093771
Slamf9 445 654 303 361 0.61 -0.714 7.88E-06 0.00093771
Slco2b1 541 621 378 310 0.594 -0.752 8.52E-06 0.00098707
Fam20c 2796 2995 2000 2119 0.712 -0.491 9.73E-06 0.00108863
Clec4a3 2036 2359 1557 1593 0.718 -0.478 1.26E-05 0.00135617
Arsb 207 310 122 152 0.534 -0.904 1.62E-05 0.00161083
Adcy7 6750 7092 5376 5360 0.776 -0.366 1.99E-05 0.00195045
Dbi 2230 2534 1763 1602 0.707 -0.5 2.03E-05 0.00196484
Neurl3 324 473 218 205 0.534 -0.904 2.06E-05 0.00198032
Dock8 6543 7923 5276 5410 0.741 -0.433 2.32E-05 0.00220558
Lrmp 215 309 141 151 0.562 -0.832 2.51E-05 0.00232483
P2ry13 199 349 142 158 0.561 -0.834 2.66E-05 0.00244789
Hp 337 505 190 224 0.493 -1.019 2.76E-05 0.00251155
Itgam 3919 2729 2797 1829 0.691 -0.533 2.78E-05 0.00251155
Frmd4b 466 706 352 322 0.584 -0.776 2.82E-05 0.00252566
Cotl1 12464 11276 9872 8123 0.756 -0.403 2.92E-05 0.00259444
Dok2 467 531 339 234 0.567 -0.819 3.10E-05 0.00273253
Ttc39a 139 169 75 73 0.48 -1.058 3.22E-05 0.00281029
Arhgap4 365 571 232 297 0.573 -0.804 3.29E-05 0.00285479
Calr 36089 38642 28136 29930 0.777 -0.364 3.49E-05 0.00297376
Fdps 1607 1636 1145 1112 0.696 -0.524 4.09E-05 0.00345887
Hspa8 10546 11221 7870 8585 0.756 -0.403 4.20E-05 0.00352554
Ptgs1 51 74 25 16 0.323 -1.629 4.29E-05 0.0035579
Sqle 2564 2502 1752 1818 0.705 -0.504 4.31E-05 0.0035579
Aldh1l1 253 355 149 200 0.576 -0.795 4.72E-05 0.00387446
Pdia3 12419 14795 9100 10748 0.73 -0.455 4.87E-05 0.00395164
Kcne3 103 171 60 70 0.483 -1.051 5.00E-05 0.00398211
Ucp2 22723 25678 18961 17934 0.764 -0.389 5.50E-05 0.00430903
Pdia4 3011 3415 2377 2385 0.742 -0.43 5.98E-05 0.00461714
Celf2 2344 2722 1853 1996 0.761 -0.394 6.09E-05 0.00467201
Pak1 391 521 275 287 0.619 -0.692 6.77E-05 0.00510099
Unc119 1585 1762 1283 1086 0.707 -0.501 6.79E-05 0.00510099
Lair1 1275 1539 833 1127 0.695 -0.525 6.97E-05 0.00519873
Siglece 327 454 193 296 0.627 -0.675 7.13E-05 0.00527759
Krt80 270 309 167 159 0.563 -0.829 7.63E-05 0.00554989
Hmgcs1 3396 3474 2706 2590 0.771 -0.376 7.96E-05 0.0057364
Mmp8 144 172 95 67 0.509 -0.974 8.44E-05 0.00592103
Cxcl14 218 220 139 74 0.469 -1.091 8.79E-05 0.00608441
Pram1 78 114 39 41 0.424 -1.237 0.00010891 0.00734886
Trf 7688 9671 6332 6698 0.755 -0.406 0.00011023 0.00739081
Fes 2061 2284 1577 1246 0.652 -0.618 0.00012115 0.00794028
Gmpr 547 637 423 369 0.669 -0.579 0.0001214 0.00794028
Rnpep 2753 3100 2190 1979 0.714 -0.485 0.0001251 0.00813224
Cd48 3875 4267 3153 3168 0.777 -0.364 0.00013243 0.0085569
Ptprs 873 827 659 448 0.643 -0.636 0.00013755 0.00883366
Rpn1 6477 6447 5216 5002 0.79 -0.339 0.0001411 0.00900765
Glul 9290 10428 7716 7571 0.776 -0.366 0.0001483 0.00941104
Syn1 128 200 88 83 0.525 -0.929 0.00015022 0.00943591
Nedd4 154 160 97 49 0.444 -1.172 0.00016235 0.01002424
Pygl 3781 4647 3170 3125 0.751 -0.413 0.00016267 0.01002424
Klhl6 438 582 313 346 0.65 -0.622 0.00017667 0.01082455
Hsd17b4 5370 6452 4516 4496 0.765 -0.386 0.00018552 0.01130157
Mllt4 638 786 459 387 0.599 -0.74 0.00019291 0.01168558
6430548M08Rik 2459 2355 1926 1718 0.756 -0.403 0.0001948 0.01168921
Deptor 846 1105 679 695 0.708 -0.498 0.00019517 0.01168921
Paqr7 308 369 214 206 0.623 -0.682 0.00020721 0.01214608
Scarb1 2258 2551 1861 1712 0.744 -0.427 0.00021359 0.01244307
Itgax 36320 37340 30225 27717 0.786 -0.348 0.00021722 0.01258576
Cmbl 289 284 192 138 0.57 -0.811 0.00022538 0.0129877
Ikbke 1898 2113 1352 1647 0.747 -0.422 0.0002351 0.01333217
Grap2 406 501 316 283 0.663 -0.593 0.00024539 0.01376869
Cfp 213 460 169 198 0.57 -0.81 0.00025142 0.01385503
Myo7a 5642 5936 4438 3860 0.718 -0.478 0.00025212 0.01385503
Pld4 2243 3536 1835 2137 0.699 -0.517 0.00024993 0.01385503
Vsig8 132 137 64 51 0.424 -1.237 0.00024919 0.01385503
Axl 17901 23475 15216 16051 0.761 -0.393 0.00026418 0.01421725
Lrrc25 141 196 84 85 0.504 -0.989 0.00026224 0.01421725
Rab3d 2507 2796 2063 2007 0.769 -0.38 0.00026941 0.0143609
Vdr 309 327 217 192 0.643 -0.637 0.00027303 0.01448166
Ly6e 5241 6903 4192 4221 0.696 -0.523 0.00028041 0.01472654
Nlrp1a 110 158 64 73 0.517 -0.952 0.00030159 0.01545787
Aldoc 3151 3486 2585 2225 0.725 -0.464 0.00033857 0.01707218
Ptpn18 58 82 23 31 0.388 -1.366 0.00033949 0.01707218
Pdk1 623 791 492 476 0.689 -0.538 0.00037305 0.01858454
Ccnd1 128 158 91 46 0.454 -1.141 0.00037917 0.01862811
Abcd1 1804 2067 1429 1386 0.73 -0.455 0.00039686 0.01931458
Marveld1 1102 1238 818 913 0.74 -0.434 0.00039707 0.01931458
Hsp90b1 21268 23093 15854 18653 0.777 -0.364 0.00040062 0.0193258
Gsn 6808 7306 5621 5372 0.778 -0.362 0.00041229 0.01971056
Siglec1 7703 9884 6503 6922 0.769 -0.378 0.00041682 0.01983792
Pdia6 5999 6592 4835 5144 0.793 -0.335 0.00046298 0.02164816
Cd101 149 242 98 130 0.593 -0.753 0.00050251 0.0230882
Slc18a1 47 47 19 12 0.325 -1.621 0.0005046 0.0230882
Matk 79 96 38 31 0.387 -1.368 0.00052568 0.02364686
Trem2 1739 1927 1480 1147 0.712 -0.49 0.00055852 0.02501831
Sulf2 4400 4851 3722 3172 0.747 -0.422 0.00057387 0.02559848
Fos 645 714 455 509 0.71 -0.494 0.00057934 0.02562817
Ddx58 787 984 621 666 0.73 -0.455 0.00059673 0.02628823
Sdc3 6359 7904 5396 5350 0.757 -0.401 0.00060557 0.02651421
Tm6sf1 1557 1879 1270 1275 0.743 -0.428 0.00060828 0.02651421
Tubb4b 1378 1425 1159 880 0.72 -0.474 0.00062809 0.02710958
Ksr2 58 63 25 16 0.333 -1.587 0.00063412 0.02716693
Snn 812 1024 595 609 0.661 -0.596 0.00063452 0.02716693
Ids 1503 1856 1158 1348 0.748 -0.419 0.00065928 0.02811442
Nbeal2 1197 1078 847 816 0.73 -0.453 0.00068992 0.02918744
Card11 5265 7004 4544 4665 0.76 -0.396 0.00069318 0.02920934
Mlec 7502 8555 6401 6027 0.776 -0.366 0.0007309 0.03067754
Plxdc2 151 271 101 136 0.571 -0.808 0.00074714 0.03111434
Cdh1 1034 856 835 580 0.742 -0.431 0.00075226 0.03120568
Capn5 210 193 108 99 0.514 -0.96 0.00080585 0.0331706
Slc25a13 256 349 171 220 0.649 -0.625 0.00082833 0.03396455
Tmem50b 1045 1165 809 854 0.754 -0.408 0.00084596 0.0345547
Il6ra 599 828 501 470 0.691 -0.534 0.0008723 0.03535976
Gm1966 289 519 249 208 0.592 -0.756 0.00089268 0.03577757
Tbxas1 1592 1934 1379 1209 0.736 -0.442 0.00091023 0.0362089
Epsti1 200 291 143 157 0.618 -0.695 0.00100739 0.03963018
Fn1 10496 11980 8076 8755 0.749 -0.417 0.0010407 0.04079024
Ost4 898 1076 745 701 0.734 -0.446 0.00108629 0.04226625
Ptk2b 4599 5196 3965 3915 0.806 -0.312 0.00115349 0.04439497
Mum1 1009 1127 707 720 0.67 -0.578 0.00116916 0.04483592
Kctd12b 1307 1712 910 1180 0.692 -0.53 0.00121513 0.04626608
Rnase4 264 253 173 175 0.669 -0.579 0.00122079 0.04631634
Abi3 652 757 467 540 0.716 -0.482 0.00126721 0.04740252
Aacs 890 847 628 633 0.724 -0.465 0.00128011 0.04755749
Rin3 1879 2185 1589 1538 0.772 -0.373 0.00129812 0.04755749
Tnc 17 106 7 4 0.128 -2.961 0.00128546 0.04755749
Itga6 463 510 340 362 0.723 -0.468 0.00131069 0.0476904
Pilra 3429 4592 2665 3309 0.747 -0.421 0.00137095 0.0495447
